Page last updated: 2024-12-05

etidronate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Etidronate is a bisphosphonate medication that is used to treat conditions such as Paget's disease of bone, hypercalcemia associated with cancer, and osteoporosis. It is also used to prevent the development of osteoporosis in patients who are at high risk. Etidronate works by inhibiting the activity of osteoclasts, which are the cells that break down bone. This action helps to reduce bone loss and increase bone density. Etidronate is typically taken by mouth, but it can also be given intravenously. It is generally well tolerated, but side effects can include gastrointestinal upset, muscle cramps, and bone pain. Etidronate has been shown to be effective in treating and preventing bone loss. However, it is important to note that etidronate can cause jawbone necrosis, especially in patients who are taking bisphosphonates for a long period of time. This is a serious side effect that can lead to bone death and the need for surgery. Etidronate is a valuable treatment option for many patients with bone disorders. However, it is important to discuss the risks and benefits of etidronate with your doctor before taking it.'

Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3305
CHEMBL ID871
CHEBI ID4907
SCHEMBL ID18607
MeSH IDM0020101

Synonyms (141)

Synonym
smr000038750
MLS002695948
MLS002207267
STK721995
c2h8o7p2
(hydroxyethylidene)diphosphonic acid
1-hydroxyethanediphosphonic acid
1000sl
1-hydroxyethane-1,1-diphosphonate
(1-hydroxyethylidene)diphosphonic acid
1-hydroxy-1,1-diphosphonoethane
diphosphonate (base)
hedp
nsc227995
oxyethylidenediphosphonic acid
phosphonic acid, (1-hydroxyethylidene)di-
1-hydroxyethane-1,1-diphosphonic acid
turpinal sl
hydroxyethanediphosphonic acid
ethane-1-hydroxy-1,1-diphosphonate
hydroxyethane-1,1-diphosphonic acid
ehdp
1-hydroxyethane-1,1-bisphosphonic acid
(1-hydroxyethylidene)bis(phosphonic acid)
dequest z 010
dequest 2015
nsc-227995
ethane-1-hydroxy-1,1-diphosphonic acid
(1-hydroxyethylidene)diphoshonic acid
dequest 2010
(1-hydroxyethane-1,1-diyl)bis(phosphonic acid)
brn 1789291
1-hydroxyethylidene-1,1-biphosphonate
nsc 227995
etidronsaeure
acide etidronique [inn-french]
phosphonic acid, 1-hydroxy-1,1-ethanediyl ester
einecs 220-552-8
acido etidronico [inn-spanish]
hsdb 5898
etidronic acid [usan:inn:ban]
rp 61
acidum etidronicum [inn-latin]
ferrofos 510
BSPBIO_000905
PRESTWICK2_000863
PRESTWICK3_000863
1-hydroxyethylidene-1,1-diphosphonic acid
2809-21-4
etidronic acid
ethane-1-hydroxy-1,1-bisphosphonate
C07736
(1-hydroxy-1-phosphono-ethyl)phosphonic acid
phosphonic acid, (1-hydroxyethylidene)bis-
etidronate
(1-hydroxy-ethylidene)diphosphonic acid
1,1,1-ethanetriol diphosphonate
DB01077
(1-hydroxyethylidene)bisphosphonic acid
acetodiphosphonic acid
1-hydroxyethane 1,1-diphosphonic acid
ethane-1-hydroxy-1,1-bisphosphonic acid
(1-hydroxyethylene)diphosphonic acid
1-hydroxyethylidene-1,1-bisphosphonate
etidronic acid (usan/inn)
D02373
BPBIO1_000997
PRESTWICK1_000863
SPBIO_002826
PRESTWICK0_000863
hydroxyethylidene diphosphonic acid
diphosphonic acid, hydroxyethylidene
bdbm50115102
(1-hydroxy-1-phosphono-ethyl)-phosphonic acid
chebi:4907 ,
m05ba01
CHEMBL871 ,
acido etidronico
acidum etidronicum
acide etidronique
FT-0668439
oedfk
H0587
hdepa
(1-hydroxy-1-phosphonoethyl)phosphonic acid
1-hydroxyethylidene-1,1-diphosphonicacid
A23202
NCGC00159352-05
NCGC00159352-04
0-02-00-00171 (beilstein handbook reference)
m2f465roxu ,
phosphonic acid, p,p'-(1-hydroxyethylidene)bis-
ec 220-552-8
unii-m2f465roxu
dtxsid6023028 ,
cas-2809-21-4
NCGC00257971-01
tox21_200417
dtxcid103028
(1-hydroxyethane-1,1-diyl)diphosphonic acid monohydrate
AKOS005524039
1-hydroxyethylidenediphosphonic acid
FT-0607934
etidronic acid [usan]
etidronic acid [inci]
etidronic acid [inn]
etidronic acid [who-dd]
etidronate [vandf]
etidronic acid [hsdb]
etidronic acid [mi]
hydroxyethylidene-1,1-diphosphonic acid
etidronic acid [mart.]
oedp
S12329
S1857
(1-hydroxyethane-1,1-diyl)diphosphonic acid
etidronic acid-d3
gtpl7184
DL-390
HY-B0302
BBL028139
SCHEMBL18607
J-504794
(1-hydroxy-1,1-ethanediyl)bis(phosphonic acid)
HMS3604E03
mfcd00070585
hedpa
Q2758338
etidronic acid-d3 sodium salt
etidronate (didronel)
1-hydroxyethane-1,1-diyldiphosphonic acid
etidronic-acid
CCG-266618
2809-21-4 (freeacid)
(1-hydroxyethan-1,1-diyl)bis(phosphonic acid)
NCGC00159352-06
etidronicacid
Z1269201561
etidronsaure
v10bx03
etidronic acid (mart.)

Research Excerpts

Overview

Etidronate is a non-nitrogen-containing bisphosphonate (non-NBP) Used for anti-bone resorptive therapy as well as having inhibitory effects on atherosclerotic plaques.

ExcerptReferenceRelevance
"Etidronate is a non-nitrogen-containing bisphosphonate. "( History of etidronate.
Chesnut, CH; Genant, HK; Harris, ST; Jackson, RD; Licata, AA; Miller, PD; Mysiw, WJ; Richmond, B; Valent, D; Watts, NB, 2020
)
2.39
"Etidronate is a non-nitrogen-containing bisphosphonate (non-NBP) used for anti-bone resorptive therapy as well as having inhibitory effects on atherosclerotic plaques. "( Etidronate down-regulates Toll-like receptor (TLR) 2 ligand-induced proinflammatory cytokine production by inhibiting NF-κB activation.
Hojo, K; Kiyoura, Y; Kobayashi-Sakamoto, M; Tamai, R, 2017
)
3.34
"Etidronate is an oral bisphosphonate compound that is known to reduce bone resorption through the inhibition of osteoclastic activity. "( Efficacy of oral etidronate for skeletal diseases in Japan.
Iwamoto, J; Sato, Y; Takeda, T, 2005
)
2.11
"Etidronate disodium is an oral bisphosphonate compound known to reduce bone resorption through the inhibition of osteoclastic activity. "( Etridronate therapy in the treatment and prevention of osteoporosis.
Adachi, JD; Hanley, DA; Ioannidis, G, 2000
)
1.75

Effects

Oral etidronate has been used successfully in the treatment of Paget's disease and for the prevention and treatment of heterotopic ossification after hip replacement and spinal cord injury. Etidronay has been found to be ineffective in patients with multiple myeloma and prostate carcinoma bone metastases.

ExcerptReferenceRelevance
"Etidronate has less and lower clinical evidences than other bisphosphonates and SERM, but still has clinical efficacy and advantage to treat osteoporotic patients."( [Etidronate for treatment of osteoporosis].
Asano, S; Itoh, M; Suzuki, A, 2009
)
1.98
"Etidronate has specific site and bone cell actions in the periodontium. "( The effect of etidronate on the periodontium of ovariectomized rats.
Berdal, A; El Ayeb, H; Ghoul-Mazgar, S; Khemiss, F; Ruhin-Poncet, B; Said, F; Saidane, D, 2012
)
2.18
"Oral etidronate has been used for 3 weeks, after failure of classical treatment."( [Etidronate per os in subcutaneous fat necrosis with hypercalcemia and nephrocalcinosis].
Bottu, J; Trullemans, B; Van Nieuwenhuyse, JP, 2007
)
1.7
"etidronate) have been associated with acute renal failure."( Safety considerations with bisphosphonates for the treatment of osteoporosis.
Civitelli, R; Emkey, R; Strampel, W, 2007
)
1.06
"Etidronate has been more efficient in reducing biological parameters, whereas calcitonin has produced a faster symptomatic response."( [Treatment of Paget's disease of bone: diphosphonates or calcitonin?].
Courvoisier, B; Davoine, GA; Jung, A, 1981
)
0.98
"Oral etidronate has been investigated but not approved for osteoporosis therapy."( Postmenopausal osteoporosis: patient choices and outcomes.
Cosman, F; Lindsay, R; Nieves, J; Walliser, J, 1995
)
0.75
"Etidronate has been used successfully in the treatment of Paget's disease and for the prevention and treatment of heterotopic ossification after hip replacement and spinal cord injury."( Critical drug appraisal: etidronate intermittent cyclic therapy for postmenopausal osteoporosis.
Miller, PD,
)
1.16
"Oral etidronate has been found to be ineffective in patients with multiple myeloma and prostate carcinoma bone metastases."( Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000
)
0.76

Actions

Etidronate can increase bone mineralization in women with osteoporosis, but will it be useful for prophylaxis? Oestrogens can prevent bone loss, but is the increased risk of breast cancer sufficient to preclude their use? Do oestrogens increase or decrease the risk of cardiovascular disease? A combination of oestrogen and progesterone may avoid the increasedrisk of uterine cancer but what are the effects of long term administration?

ExcerptReferenceRelevance
"Etidronate, at the lower concentration, significantly increased the expression of interleukin (IL)-6 (p=0.03) and IL-8 (p=0.04). "( Pro-inflammatory and anti-angiogenic effects of bisphosphonates on human cultured retinal pigment epithelial cells.
Cui, J; Forooghian, F; Matsubara, J; Or, C, 2013
)
1.83
"Etidronate has less and lower clinical evidences than other bisphosphonates and SERM, but still has clinical efficacy and advantage to treat osteoporotic patients."( [Etidronate for treatment of osteoporosis].
Asano, S; Itoh, M; Suzuki, A, 2009
)
1.98
"Etidronate can increase bone mineralization in women with osteoporosis, but will it be useful for prophylaxis? Oestrogens can prevent bone loss, but is the increased risk of breast cancer sufficient to preclude their use? Do oestrogens increase or decrease the risk of cardiovascular disease? A combination of oestrogen and progesterone may avoid the increased risk of uterine cancer but what are the effects of long term administration? Do the potential benefits of hormone therapy justify the costs and treatment of large numbers of women who without therapy would never have developed complications attributable to oestrogen lack? (Herman J: Fam Phys 1990; 18: 39-40) Given these uncertainties, is postmenopausal administration of hormones reasonable or prudent? The current literature does not provide adequate answers to these questions."( Selections from current literature: hormone therapy in postmenopausal women.
Froom, J, 1991
)
1

Treatment

Etidronate treatment of 5 mg/kg, 5 days/week was administered for 2 weeks and exercised on a treadmill for 30 m/min, 60 min/day. Etidronates appeared to be safe in patients with established corticosteroid induced osteoporosis. Treatment with 400 mg daily, induced total regression of severe, disabling periarticular calcifications during a treatment period of 42 months.

ExcerptReferenceRelevance
"Etidronate treatment halts systemic arterial calcification in PXE. "( Etidronate halts systemic arterial calcification in pseudoxanthoma elasticum.
Bartstra, JW; de Jong, PA; den Harder, AM; Isgum, I; Kranenburg, G; Mali, WPTM; Spiering, W; Wijsman, A; Wolf, B; Wolterink, JM, 2020
)
3.44
"Etidronate or vehicle treatment (5 mg/kg/day, daily, subcutaneous injection) was initiated after glucocorticoid administration (30 mg/kg/day, on alternate days, orally) for 6 weeks and was continued for 3 weeks."( Short-term etidronate treatment prevents glucocorticoid-induced bone debility of the mandible in growing rats.
Fujita, Y; Konoo, T; Maki, K, 2008
)
1.46
"Etidronate treatment improved the glucocorticoid-induced decrease in bone strength and increased density in trabecular and cortical bone above the untreated control level, but had no significant effects on the reduction in mandibular length."( Short-term etidronate treatment prevents glucocorticoid-induced bone debility of the mandible in growing rats.
Fujita, Y; Konoo, T; Maki, K, 2008
)
1.46
"Etidronate-treated rats exhibited extensive morphological changes in the secretory-stage enamel organic ECM inclusive nonbirefringent conspicuous incremental lines, but presented optical retardation values similar to those showed by control rats (p > 0.05)."( Birefringence of the secretory-stage enamel organic extracellular matrix from rats submitted to successive injections of bisphosphonates.
do Espírito Santo, AR; Frozoni, MR; Line, SR; Novaes, PD; Ramos-Perez, FM, 2010
)
1.08
"Etidronate treatment had no effect on circulating OPG levels, although the significant decline in PINP and ICTP (P=0.001 and P=0.04 respectively) reflected the efficacy of the anti-resorptive therapy. "( Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis.
Koivula, MK; Konttinen, YT; Laasonen, L; Mandelin, J; Risteli, J; Valleala, H, 2003
)
2.05
"Etidronate treatment at 200 mg/day resulted in the improvement of bone metabolism markers and bone scintigraphy findings."( Two cases of monostotic Paget's disease: effects of bisphosphonate.
Aoki, N; Harada, T; Hoshiro, M; Iwai, H; Miyatake, T; Nishimura, A; Ohno, Y, 2003
)
1.04
"Etidronate treatment (10 mg/kg, daily subcutaneous injection) was initiated 2 weeks after surgery and was continued for 2 weeks."( Differential effect of short-term etidronate treatment on three cancellous bone sites in orchidectomized adult rats.
Ichimura, S; Iwamoto, J; Takeda, T, 2004
)
1.32
"Oral etidronate treatment is well-tolerated and capable of improving bone mineralization in patients with cystic fibrosis. "( [Effect of oral biphosphonates in patients with cystic fibrosis and low bone mineral density].
Audran, M; Duveau, E; Giniès, JL; Leblanc, M; Leboucher, B; Ringuier, B; Troussier, F, 2004
)
0.84
"Oral etidronate treatment may also help to transiently relieve metastatic cancer bone pain followed by a decrease in abnormally raised bone resorption in patients with painful bone metastases from primary cancer sites, such as the lung, breast and prostate."( Efficacy of oral etidronate for skeletal diseases in Japan.
Iwamoto, J; Sato, Y; Takeda, T, 2005
)
1.12
"Etidronate treatment sustained the lumbar BMD following a reduction in the urinary NTX level and improved back pain, while alendronate treatment reduced the urinary NTX level more significantly, resulting in an increase in the lumbar BMD, and similarly improved back pain."( Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
Iwamoto, J; Sato, Y; Takeda, T; Uzawa, M, 2005
)
1.32
"The etidronate group was treated with etidronate 400 mg once daily for 14 days followed by 76 days of 500 mg of elementary calcium once daily; this cycle was repeated every 3 months."( The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment.
Bakker, K; Kerkhoff, JF; Montessori, ML; Netelenbos, JC; Scheele, WH, 1997
)
1.17
"Etidronate treatment of 5 mg/kg, 5 days/week was administered for 2 weeks and exercised on a treadmill for 30 m/min, 60 min/day, 5 days/week for 10 weeks."( Effects of exercise training and etidronate treatment on bone mineral density and trabecular bone in ovariectomized rats.
Akamine, T; Goshi, N; Kurata, H; Sakou, T; Tamaki, H, 1998
)
1.3
"Etidronate treatment administered for 36 months reversed lumbar spine bone loss, and appeared to be safe in patients with established corticosteroid induced osteoporosis."( 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis.
Adachi, JD; Bensen, WG; Bianchi, F; Cividino, A; Goldsmith, CH; Gordon, M; Ioannidis, G; Kaminska, E; Petrie, A; Scocchia, T; Sebaldt, RJ; Stephenson, GF, 1999
)
2.03
"Etidronate treatment (10 mg/kg per day subcutaneously) was initiated 2 weeks after surgery and was continued for 2 weeks."( Effect of etidronate on bone in orchidectomized and sciatic neurectomized adult rats.
Ichimura, S; Iwamoto, J; Katsumata, T; Takeda, T; Tanaka, T; Toyama, Y, 2002
)
1.44
"Treatment with etidronate had no effect on bone parameters in the WT mice; however, the Enpp1-/- mice displayed an increased structural model index (SMI; P<0.05)."( Effects of etidronate on the Enpp1⁻/⁻ mouse model of generalized arterial calcification of infancy.
Huesa, C; MacRae, VE; Millán, JL; Staines, KA, 2015
)
1.15
"Treatment with etidronate, 400 mg daily, induced total regression of severe, disabling periarticular calcifications during a treatment period of 42 months in a patient with chronic kidney disease on dialysis treatment. "( [Regression of severe periarticular calcifications during treatment with bisphosphonate in a dialysis patient].
Larsen, NA; Obad, D; Pedersen, EB, 2010
)
0.71
"Treatment with etidronate suppressed this increase."( Preliminary study of etidronate for prevention of corticosteroid-induced osteoporosis caused by oral glucocorticoid therapy.
Furukawa, F; Hata, M; Hattori, M; Ikeda, T; Kaminaka, C; Kanazawa, N; Nishide, T; Ohta, C; Tsujioka, K; Uede, K; Yamamoto, Y, 2011
)
1.03
"Treatment with etidronate is effective in patients with glucocorticoid-induced osteoporosis."( Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases.
Burmester, GR; Buttgereit, F; Grauer, A; Loddenkemper, K,
)
0.79
"Treatment with etidronate disodium resulted in a temporary 40% reduction in serum alkaline phosphatase and 24 h urine hydroxyproline excretion, with reduction in serum osteocalcin from two times the upper limit of normal to a subnormal level."( Hereditary hyperphosphatasia: 20 year follow-up and response to disodium etidronate.
Dempster, D; Lindsay, R; Parisien, M; Shane, E; Singer, F; Siris, E, 1994
)
0.86
"Treatment with etidronate at a dose of 6 mg/kg per day on alternate months resulted in a complete recovery of bone symptoms and normalization of metabolic parameters of bone turnover; unexpectedly, a sustained haematological improvement was also observed after several months of therapy, suggesting that bone marrow microenvironment improvement was able to restore a nearly normal haemopoiesis."( Clinical and haematological improvement induced by etidronate in a patient with idiopathic myelofibrosis and osteosclerosis.
Camaschella, C; Cesano, L; Guerrasio, A; Mazza, U; Sivera, P, 1994
)
0.88

Toxicity

The acute intravenous toxicity of disodium dihydrogen (1-hydroxyethylidene)diphosphonate (etidronate disodium; I) and the mechanism of this toxic response have been investigated in 40 beagle dogs. These adverse drug reactions are not limited to alendronate and may also be induced by etidronates and risedrons. Bayesian network meta-analysis showed that equivalence was demonstrated according to margins around ±10%.

ExcerptReferenceRelevance
"The acute intravenous toxicity of disodium dihydrogen (1-hydroxyethylidene)diphosphonate (etidronate disodium; I) and the mechanism of this toxic response have been investigated in 40 beagle dogs."( Acute intravenous infusion of disodium dihydrogen (1-hydroxyethylidene)diphosphonate: mechanism of toxicity.
Francis, MD; Slough, CL, 1984
)
0.49
" Risedronate was well tolerated, had a good safety profile, and was not associated with gastrointestinal adverse events."( Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
Adami, S; Devogelaer, JP; Eusebio, RA; Hughes, RA; Laan, RF; Reid, DM; Sacco-Gibson, NA; Wenderoth, DH, 2000
)
0.31
" No major adverse effects were observed."( Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Carpentier, P; Caty, A; Depreux, P; Kolesnikov-Gauthier, H; Sulman, C; Vennin, P, 2000
)
0.31
"186Re-HEDP provides safe symptomatic relief of pain in prostate cancer patients."( Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Carpentier, P; Caty, A; Depreux, P; Kolesnikov-Gauthier, H; Sulman, C; Vennin, P, 2000
)
0.31
" Repeat BMD measurements were obtained in 88 patients, including 11 who stopped their bisphosphonate therapy within the first year of use because of adverse events."( Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.
Béra-Louville, A; Cortet, B; Delcambre, B; Gauthier, A; Gauthier, P; Marchandise, X, 2001
)
0.58
" Conversely, adverse effects, most notably gastrointestinal symptoms, were more common with alendronate, so that premature treatment discontinuation because of adverse events were more common in the alendronate group."( Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.
Béra-Louville, A; Cortet, B; Delcambre, B; Gauthier, A; Gauthier, P; Marchandise, X, 2001
)
0.58
" Some bisphosphonates have been associated with upper gastrointestinal (GI) tract adverse effects."( Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.
Adami, S; Bolognese, MA; Ernst, TF; Ettinger, MP; Josse, RG; Lindsay, R; Mulder, H; Roberts, A; Stevens, KP; Taggart, H; Zippel, H, 2002
)
0.31
" The risk of an adverse upper GI event increases when these drugs are used concurrently with nonsteroidal anti-inflammatory drug (NSAID) therapy, but this incidence is no more than that observed with concurrent placebo and NSAID therapy."( Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity.
Baker, DE, 2002
)
0.31
" The most frequently reported adverse events are gastrointestinal complaints and oesophageal ulcers."( [Psychiatric side effects associated with diphosphonate treatment].
van der Klauw, MM; Wolffenbuttel, BH, 2003
)
0.32
"To evaluate the frequency of upper gastrointestinal (GI) tract adverse events associated with risedronate during two (2-year) randomized, double-blind, parallel-group, placebo-controlled studies."( Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial.
Adami, S; Barton, IP; Bensen, WG; Cline, GA; Cohen, SB; Hosterman, MA; Pavelka, K, 2005
)
0.33
" The number of upper GI tract adverse events was similar between treatment groups, with no dose-related response: 161 for placebo, 176 for rlsedronate at 5 mg/d, and 150 for risedronate at 15 mg/d."( Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial.
Adami, S; Barton, IP; Bensen, WG; Cline, GA; Cohen, SB; Hosterman, MA; Pavelka, K, 2005
)
0.33
"The results of this study show that risedronate regimens at 5 mg/d or 15 mg/d as well as once weekly at 35 mg or 50 mg are not associated with an increased frequency of upper GI tract adverse events, even in patients who have an increased risk for such events."( Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial.
Adami, S; Barton, IP; Bensen, WG; Cline, GA; Cohen, SB; Hosterman, MA; Pavelka, K, 2005
)
0.33
" Risedronate was safe and effective in osteoporotic women with mild, moderate, or severe age-related renal impairment."( Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Barton, IP; Boonen, S; Burgio, DE; Dunlap, LE; Miller, PD; Roux, C, 2005
)
0.33
" Risedronate is a pyridinyl bisphosphonate well established as safe and effective in the treatment and prevention of osteoporosis."( Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Barton, IP; Boonen, S; Burgio, DE; Dunlap, LE; Miller, PD; Roux, C, 2005
)
0.33
" The incidences of overall adverse events and of renal function-related adverse events were similar in the placebo and risedronate 5 mg groups regardless of renal function."( Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Barton, IP; Boonen, S; Burgio, DE; Dunlap, LE; Miller, PD; Roux, C, 2005
)
0.33
"These findings show that risedronate is safe and effective in osteoporotic women with age-related mild, moderate, or severe renal impairment."( Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Barton, IP; Boonen, S; Burgio, DE; Dunlap, LE; Miller, PD; Roux, C, 2005
)
0.33
" The changes were compared in bone mineral density (BMD), bone metabolism markers and adverse events after 12 months oral administration of risedronate sodium."( Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis.
Chen, L; Deng, X; Li, Y; Zhang, Z, 2005
)
0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"Oral daily bisphosphonates carry a potential for gastrointestinal (GI) adverse events, which has been partly addressed by introducing once-weekly regimens."( Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM, 2006
)
0.33
" RCTs have demonstrated that the incidence of gastrointestinal tract adverse events in postmenopausal osteoporotic women treated with bisphosphonates and placebo are similar, and also the long-term efficacy and safety of alendronate and risedronate."( Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto, J; Sato, Y; Takeda, T, 2006
)
0.33
"To examine in a major cohort of patients whether or not musculoskeletal adverse effects (MAEs), similar to those seen in intravenous bisphosphonates (BP), might occur also in high dosage oral treatment regimens with alendronate (ALN) and risedronate (RSN)."( Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.
Bock, O; Boerst, H; Degner, C; Felsenberg, D; Stephan-Oelkers, M; Thomasius, FE; Valentine, SM,
)
0.13
" Risedronate administration in the dose which is considered to be comparable to a dose of risedronate used for treatment of osteoporosis in women seems to be safe in terms of effects on mouse haematopoiesis."( Risedronate has no adverse effects on mouse haematopoiesis.
Broulík, P; Necas, E; Pelichovská, T; Sefc, L, 2007
)
0.34
" The review specifically considers upper gastrointestinal (UGI) adverse events (AEs), renal toxicity, influenza-like illness, osteonecrosis of the jaw and evidence on how to treat or prevent these events."( Safety considerations with bisphosphonates for the treatment of osteoporosis.
Civitelli, R; Emkey, R; Strampel, W, 2007
)
0.34
" The aim of this study was to compare the adverse effects (AEs) of alendronate, etidronate and risedronate prescribed in a non-selected population, attending a single institution on an outpatient basis."( Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases.
Anastasilakis, AD; Avramidis, A; Goulis, DG; Kita, M,
)
0.36
" Bone mineral density, bone turnover markers, fractures, and adverse events were evaluated."( Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, PD; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2008
)
0.35
" The incidence of adverse events, adverse events leading to withdrawal, and upper gastrointestinal tract adverse events were similar in the 2 treatment groups."( Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, PD; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2008
)
0.35
" In placebo controlled trials it has been shown to be safe and effective in preventing fractures."( Review of the safety and efficacy of risedronate for the treatment of male osteoporosis.
Adachi, JD; Bobba, R, 2007
)
0.34
" Risedronate 75 mg twice monthly was effective and safe suggesting a new, convenient dosing schedule."( Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results.
Benhamou, CL; Delmas, PD; Eusebio, R; Man, Z; Matzkin, E; McClung, MR; Olszynski, WP; Recker, RR; Tlustochowicz, W; Zanchetta, J, 2008
)
0.35
" Although these agents are generally well tolerated, serious gastrointestinal adverse events, including hospitalization for gastrointestinal bleed, may arise."( Comparative gastrointestinal safety of weekly oral bisphosphonates.
Brookhart, MA; Cadarette, SM; Katz, JN; Levin, R; Solomon, DH; Stedman, MR; Stürmer, T, 2009
)
0.35
"The objective of this study was to compare the changes on bone mineral density, and the effects on persistence and adverse events in patients treated for postmenopausal osteoporosis with generic alendronate or with branded alendronate (Fosamax®) or branded risedronate (Actonel®) once weekly."( Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
Möller, G; Ringe, JD, 2009
)
0.35
"Retreatments with (186)Re-HEDP under zoledronic acid provide continuing effectiveness in metastatic bone pain and are safe enough, if an acceptable baseline hematologic status exists."( Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice.
Baziotis, N; Limouris, GS; Zafeirakis, A; Zissimopoulos, A, 2009
)
0.35
" Outcomes of adverse events were defined as inflammatory conditions of the jaw, including osteonecrosis; major jaw surgery for necrotic or inflammatory conditions; or jaw surgeries for malignancies."( Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S.
Hay, JW; Jeffcoat, MK; Seal, B; Skrepnek, GH; Tangirala, M; Watts, NB,
)
0.13
" Bone mineral density (BMD), bone turnover markers (BTMs), fractures, and adverse events were evaluated."( Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
Balske, A; Benhamou, CL; Bolognese, MA; Brown, JP; Burgio, DE; McClung, MR; McCullough, LK; Miller, PD; Recker, RR; Sarley, J; Zanchetta, J, 2012
)
0.38
" The incidence of adverse events leading to withdrawal and serious adverse events were similar across treatment groups."( Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
Balske, A; Benhamou, CL; Bolognese, MA; Brown, JP; Burgio, DE; McClung, MR; McCullough, LK; Miller, PD; Recker, RR; Sarley, J; Zanchetta, J, 2012
)
0.38
" However, there seems to be a limited awareness that oral bisphosphonates can also induce adverse effects in the soft tissues of the oral cavity, as indicated by the paucity of reported cases in the literature."( Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity.
Kharazmi, M; Persson, U; Warfvinge, G, 2012
)
0.38
"The database of the Medical Products Agency-Sweden was searched for adverse effects from oral bisphosphonates manifesting in the oral and maxillofacial region."( Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity.
Kharazmi, M; Persson, U; Warfvinge, G, 2012
)
0.38
"A total of 83 cases of adverse reactions to oral bisphosphonates were retrieved from the search."( Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity.
Kharazmi, M; Persson, U; Warfvinge, G, 2012
)
0.38
" These adverse drug reactions are not limited to alendronate and may also be induced by etidronate and risedronate."( Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity.
Kharazmi, M; Persson, U; Warfvinge, G, 2012
)
0.6
" The safety of risedronate was evaluated based on adverse events, laboratory data, vital signs, and physical examination results."( Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
Boonen, S; Eusebio, R; Lorenc, RS; Orwoll, ES; Stoner, KJ; Wenderoth, D, 2012
)
0.38
" Bone mineral density (BMD), bone turnover markers, new vertebral fractures, and adverse events were evaluated."( Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, P; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2013
)
0.39
" The incidence of adverse events, adverse events leading to withdrawal, and upper gastrointestinal tract adverse events were similar in the two treatment groups."( Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, P; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2013
)
0.39
"Zoledronate, at 100μM, was toxic to all types of cells tested, while its toxicity varied among cells at both 1 and 10μM."( In vitro cytotoxicity of zoledronate (nitrogen-containing bisphosphonate: NBP) and/or etidronate (non-NBP) in tumour cells and periodontal cells.
Dohdoh, M; Endo, Y; Kuroishi, T; Nagai, Y; Ohki, A; Oizumi, T; Sugawara, S; Tanaka, Y, 2013
)
0.61
" An investigation of the cytotoxicity of the RA-CSC systems upon osteoblast-like cells showed no toxic effects of concentrations up to 2%."( Preparation, characterization, release kinetics, and in vitro cytotoxicity of calcium silicate cement as a risedronate delivery system.
Gong, T; Häfeli, UO; Sun, C; Troczynski, T; Wang, Z; Yang, Q; Zhang, Y, 2014
)
0.4
" Overall and serious adverse events were similar between groups."( Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Brown, JP; Fahrleitner-Pammer, A; Ferreira, I; Hawkins, F; Ho, PR; Hofbauer, LC; Micaelo, M; Minisola, S; Papaioannou, N; Roux, C; Siddhanti, S; Stone, M; Wagman, RB; Wark, JD; Zillikens, MC, 2014
)
0.4
" Bone mineral density (BMD), biochemical markers of bone metabolism, fractures, and adverse events (AEs) were evaluated."( Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
Hagino, H; Horii, S; Kishimoto, H; Nakamura, T; Ohishi, H, 2014
)
0.4
"The data on gastrointestinal side effects (47 trials) indicated that alendronate, risedronate etidronate, and zolendronate have similar rates of the adverse effects; application of Bayesian network meta-analysis showed that equivalence was demonstrated according to margins around ±10%."( Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference.
Fadda, V; Maratea, D; Messori, A; Trippoli, S, 2015
)
0.64

Pharmacokinetics

ExcerptReferenceRelevance
" Half-life times of 186Re in three blood fractions (whole blood, plasma and plasma water) were 40."( Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
de Klerk, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1992
)
0.28
" Pharmacokinetic parameters were estimated by simultaneous analysis of risedronate serum concentration and urinary excretion rate-time data."( The effect of dosing regimen on the pharmacokinetics of risedronate.
Clay, ME; Heise, MA; Melson, CW; Mitchell, DY; Nesbitt, JD; Pallone, KA; Russell, DA, 1999
)
0.3
" Mean Cmax (0."( Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers.
Brezovic, CP; Eusebio, RA; Kelly, SC; Mitchell, DY; Nesbitt, JD; Pallone, KA; Powell, JH; Sacco-Gibson, NA; Thompson, GA, 2000
)
0.31

Compound-Compound Interactions

The study tested the stability of NaOCl solutions when combined with a novel product for clinical use, Dual Rinse HEDP. CF resistance of 100 instruments (50 ProGlider and 50 WaveOne Gold Glider) was tested in sodium hypochlorite solutions alone (NaOCl) or in combination with etidronate.

ExcerptReferenceRelevance
"These preliminary data suggest that the addition of cyclic sodium etidronate in combination with low-dose norethindrone to GnRH agonists is an effective means of ameliorating the hypoestrogenic side effects induced by GnRH agonist alone."( Effects of sodium etidronate in combination with low-dose norethindrone in patients administered a long-acting GnRH agonist: a preliminary report.
Fournet, N; Judd, HL; Surrey, ES; Voigt, B, 1993
)
0.86
"Therapies utilizing intermittent human parathyroid hormone(1-34) (hPTH[1-34]) in combination with other agents have recently been proposed as possible anabolic regimens for the treatment of osteoporosis."( Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)(2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone.
Boyce, RW; Eriksen, EF; Franks, AF; Jankowsky, ML; Paddock, CL, 1996
)
0.29
" The purpose was to determine the effects of the anti-resorptive agents alone and in combination with intermittent PTH on bone formation in the mandible and a long bone in the aged ovariectomized (Ovx) rat."( Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone.
Hunziker, J; Miller, SC; Wronski, TJ, 2000
)
0.31
"The relationship between bone turnover and bone tissue and material properties was examined in ovariectomized (OVX) rats treated with risedronate in combination with or without vitamin K2."( Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2.
Ikeda, S; Ito, M; Nakamura, T; Otomo, H; Phipps, RJ; Sakai, A; Tanaka, S, 2004
)
0.32
"To investigate the effects of vitamin K2 (Vit K2) alone or in combination with etidronate and risedronate on bone loss, osteoclast induction, and inflammation in patients with rheumatoid arthritis (RA)."( Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K, 2008
)
0.81
"Vit K2 alone or in combination with bisphosphonates for treatment of osteoporosis in patients with RA may inhibit osteoclast induction via decreases in levels of RANKL."( Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K, 2008
)
0.58
" The anti-tumor activities of risedronate in combination with carboplatin, doxorubicin, vincristine or etoposide were assayed with CalcuSyn (Biosoft)."( Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
Kawasoe, Y; Komiya, S; Minami, S; Murayama, T; Ueno, Y; Yamashita, Y; Yokouchi, M,
)
0.13
" The primary end-point was to establish the maximum tolerable dose (MTD) of capecitabine when combined with (188)Re-HEDP."( (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
Bosma, TB; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2009
)
0.35
"Capecitabine may be safely used in combination with (188)Re-HEDP in a dose of 2,500 mg/m(2) per day and 37 MBq/kg, respectively."( (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
Bosma, TB; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2009
)
0.35
" These results suggested that ECT in combination with risedronate was more effective than risedronate alone for reducing back pain in postmenopausal women with osteoporosis."( Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis.
Iwamoto, J; Takakuwa, M, 2012
)
0.38
" A total of 180 women with low bone mineral density were randomly divided into four groups, one in which sodium risedronate was administered with sodium rabeprazole and one in which only risedronate was administered (BP + PPI and BP groups, respectively)."( The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis.
Itoh, S; Sekino, Y; Shinomiya, K; Takeda, S, 2013
)
0.39
" Their use as single agents with dose escalations, in combination with biphosphonates or chemotherapy is well known in the peer-reviewed literature; however, little is known about the combination between different agents."( Radionuclide therapy of painful bone metastases--a comparative study between consecutive radionuclide infusions, combination with chemotherapy, and radionuclide infusions alone: an in vivo comparison of their effectiveness.
Gouliamos, A; Limouris, GS; Sideras, PA; Stavraka, A, 2013
)
0.39
" We aimed to evaluate the effects of risedronate alone or combined with vitamin K2 on serum ucOC, OC, and incidence of vertebral fractures in elderly osteoporotic patients."( Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis.
Aizawa, T; Chida, S; Ebina, T; Hongo, M; Ishikawa, Y; Kasukawa, Y; Miyakoshi, N; Nozaka, K; Saito, H; Shimada, Y, 2014
)
0.4
" In both dose levels, cabazitaxel (4 cycles of cabazitaxel 25 mg/m + 2 cycles of cabazitaxel 20 mg/m in level 1, and 6 cycles of cabazitaxel 25 mg/m in level 2) were combined with 2 cycles of Re-HEDP 40 MBq/kg (1."( A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial.
Bloemendal, HJ; Bouman-Wammes, EW; de Klerk, JMH; van den Eertwegh, AJM; van Dodewaard-de Jong, JM; Verheul, HMW, 2017
)
0.46
"To assess the stability of NaOCl solutions when combined with a novel product for clinical use, Dual Rinse HEDP, which contains etidronate (1-hydroxyethane 1,1-diphosphonate)."( Short-term storage stability of NaOCl solutions when combined with Dual Rinse HEDP.
Mohn, D; Zehnder, M; Zeltner, M; Zollinger, A, 2018
)
0.69
" CF resistance of 100 instruments (50 ProGlider and 50 WaveOne Gold Glider) was tested in sodium hypochlorite solutions alone (NaOCl) or in combination with etidronate (NaOCl/HEBP)."( Body temperature fatigue behaviour of reciprocating and rotary glide path instruments in sodium hypochlorite solutions alone or combined with etidronate.
Arias, A; Macorra, JC; Perez-Higueras, JJ; Perez-Villalba, D; Peters, OA, 2021
)
1.02

Bioavailability

At low etidronate concentrations and short exposure times, the salicylic acid absorption rate was significantly increased compared with saline controls. Considering low bioavailability of bisphosphonates when administered orally, subsequent studies tested the mice with subcutaneous injections of etidrone.

ExcerptReferenceRelevance
" At low etidronate concentrations and short exposure times, the salicylic acid absorption rate was significantly increased compared with saline controls."( Dose-dependent effect of calcium and magnesium etidronate on salicylic acid absorption in the rat.
Dittert, LW; Shrewsbury, RP; Wurster, DE, 1985
)
0.96
"08 M, the rate of absorption was significantly greater than would be expected if passive diffusion was the only mechanism responsible for absorption."( Dose-dependent absorption of disodium etidronate.
Chungi, VS; Dittert, LW; Gural, RP; Shrewsbury, RP, 1985
)
0.54
" Although newer bisphosphonates are more potent, oral bioavailability remains < 1%."( Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000
)
0.31
" Low oral bioavailability is the most likely reason for this difference."( Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000
)
0.31
"4), is probably the most potential prodrug candidate reported to enhance the oral bioavailability of etidronate."( Bisphosphonate prodrugs: synthesis and in vitro evaluation of alkyl and acyloxymethyl esters of etidronic acid as bioreversible prodrugs of etidronate.
Järvinen, T; Niemi, R; Taipale, H; Turhanen, P; Vepsäläinen, J, 2000
)
0.72
" Since ISA-13 is well absorbed through mucose tissues, we suggest that ISA-13 efficacy on reducing bone loss should be tested by its application on the mucosal tissue."( The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model.
Binderman, I; Breuer, E; Golomb, G; Yaffe, A, 2000
)
0.31
" The oral bioavailability of BPs is ca."( Bisphosphonate prodrugs.
Vepsäläinen, JJ, 2002
)
0.31
"Food-drug interactions may reduce the bioavailability of drugs taken after meals (negative food effect)."( Effect of administration site in the gastrointestinal tract on bioavailability of poorly absorbed drugs taken after a meal.
Kamaguchi, R; Kataoka, M; Kokubo, H; Kozaki, T; Masaoka, Y; Sakuma, S; Tanno, FK; Yamashita, S, 2007
)
0.34
" However, copies of alendronic acid tablets are approved based on the results of single-dose bioavailability studies in healthy subjects and this is not adequate to establish similar disintegration characteristics."( In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications.
Crail, DJ; Dansereau, RJ; Perkins, AC, 2008
)
0.35
"Adducts based on a bisphosphonate drug (sodium risedronate) and titanium dioxide (TiO(2)) particles have been developed and characterized in order to improve the bioavailability of orally administrated bisphosphonates."( Particulate adducts based on sodium risedronate and titanium dioxide for the bioavailability enhancement of oral administered bisphosphonates.
Beggiato, S; Bignozzi, CA; Bozzi, P; Dalpiaz, A; Dissette, V; Ferraro, L; Leo, E; Pasti, L; Vighi, E, 2010
)
0.36
"This study was designed to develop a sensitive and rapid method for the quantitation of risedronate in human urine using ultra-performance liquid chromatography with ultra-violet detector (UPLC-UV) and to compare bioavailability parameter of 5, 35 and 150 mg risedronate."( UPLC-UV method for determination of risedronate in human urine.
Chung, YH; Jeong, JH; Lim, CH; Seo, YH, 2014
)
0.4
"The present study was performed to compare the bioavailability of 2 risedronate sodium 35 mg film-coated tablet formulations (test formulation and reference formulation)."( Bioequivalence study of two risedronate sodium film-coated tablet formulations in healthy volunteers.
Handayani, LR; Rosa, TA; Setiawati, A; Setiawati, E; Sholeh, AB; Simanjuntak, R; Utami, BS; Yunaidi, DA, 2014
)
0.4
" However, its oral efficacy is restricted due to its low bioavailability and severe gastrointestinal adverse effects."( Ionic complex of risedronate with positively charged deoxycholic acid derivative: evaluation of physicochemical properties and enhancement of intestinal absorption in rats.
Byun, Y; Park, JW, 2014
)
0.4
" Taken together, the results of this study suggest that chitosan-coated liposomes containing risedronate should be effective for improving the bioavailability of risedronate."( Effective mucoadhesive liposomal delivery system for risedronate: preparation and in vitro/in vivo characterization.
Han, HK; Jung, IW, 2014
)
0.4
" The low oral bioavailability and known dosing limitations due to food interactions of bisphosphonates have led to development of an oral delayed-release dose form of risedronate 35 mg to be taken weekly, before or after breakfast."( Bone safety with risedronate: histomorphometric studies at different dose levels and exposure.
Chavassieux, P; Lundy, MW; McClung, MR; Recker, RR; Ste-Marie, LG, 2015
)
0.42
"One approach for the enhancement of oral drug bioavailability is the technique of nanoparticle preparation."( Preparation of risedronate nanoparticles by solvent evaporation technique.
Dedkova, K; Devinsky, F; Jampilek, J; Peikertova, P; Pisarcik, M; Placha, D; Vaculikova, E, 2014
)
0.4
" Considering low bioavailability of bisphosphonates when administered orally, subsequent studies tested the mice with subcutaneous injections of etidronate."( Dual Effects of Bisphosphonates on Ectopic Skin and Vascular Soft Tissue Mineralization versus Bone Microarchitecture in a Mouse Model of Generalized Arterial Calcification of Infancy.
Kingman, J; Levine, MA; Li, Q; Sundberg, JP; Uitto, J, 2016
)
0.63

Dosage Studied

The mean aorta to plasma ratios of clodronate, etidronate and pamidronates were, respectively, 2.13 patients with polyosseous Paget's disease were treated for a mean period of 7 months with disodium etidroneate (EHDP)

ExcerptRelevanceReference
" Measurement of urinary excretion of EHDP was used to define the best dosage regimen."( Biochemical and clinical effects of ethane-1-hydroxy-1,1-diphosphonate in calcium nephrolithiasis.
Baumann, JM; Bisaz, S; Fleisch, H; Wacker, M, 1978
)
0.26
" A dose-response study with two compounds also revealed the same close correlation."( Relation between bone mineralization, Ca absorption, and plasma Ca in phosphonate-treated rats.
Bonjour, JP; Fleisch, H; Russell, RG; Schenk, R; Trechsel, U, 1977
)
0.26
" Ultrastructural studies on osteoclasts from EHDP-treated rats showed a general decrease in their vacuolization and amount of organelles as dosage of EHDP increased."( Ethane-1-hydroxy-1, 1-diphosphonate (EHDP). Effects on growth and modeling of the rat tibia.
Jee, WS; Miller, SC, 1975
)
0.25
" Direct analyses of dog bones either 90 days after a single dose or 365 days after cessation of chronic dosing indicate a more rapid bone clearance of EHDP than predicted by the initial power law."( Retention of etidronate in human, dog, and rat.
Francis, MD; Kasting, GB, 1992
)
0.65
" We conclude that EHDP therapy used in this dosage schedule does not have a clinically significant impact in multiple myeloma."( Effect of daily etidronate on the osteolysis of multiple myeloma.
Belch, AR; Bergsagel, DE; Johnston, D; O'Reilly, S; Pater, J; Sutton, D; Wilson, J; Wilson, K; Zee, B, 1991
)
0.63
" The author discusses the administration, dosage and side effects, and results of current studies."( Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
Coleman, RE, 1991
)
0.28
" The two lesions in the labial dentine fully developed with a dosage of 10 mg/ P/kg or larger, and with 15 mg P/kg or larger, gross hypoplastic lesions developed."( 1-Hydroxyethylidene-1,1-bisphosphonate (HEBP) simultaneously induces two distinct types of hypomineralization in the rat incisor dentine.
Adachi, Y; Hong, SS; Ogawa, Y; Yagi, T, 1989
)
0.28
" When the chicks were dosed with [3H]calcitriol, significantly lower concentrations of the sterol were detected in the duodena of EHDP-treated birds."( The effect of disodium ethane-1-hydroxy-1,1-diphosphonate on the metabolism of calcitriol in chicks.
Edelstein, S; Lidor, C; Meyer, MS; Wasserman, RH, 1987
)
0.27
" Group A was treated with calcitonin and calcium, at the dosage indicated above, for 10 days a month during 6 months."( Biochemical assessment of acute and chronic treatment of Paget's bone disease with calcitonin and calcium with and without biphosphonate.
Espinós, D; Hernández, D; Hernández, ER; Rico, H; Younes, M, 1988
)
0.27
"13 patients with polyosseous Paget's disease were treated for a mean period of 7 months with disodium etidronate (EHDP, ethylidene-1-hydroxy-1,1-diphosphonate); the average daily dosage was 5 mg/kg body weight."( [EHDP (ethylidene-1-hydroxy-1,1-diphosphonate) in the treatment of polyosseous Paget disease].
Frühwald, F; Kolbe, H; Kovarik, J; Niebauer, B; Woloszczuk, W, 1985
)
0.48
" The patients received an oral dosage of about 20 mg/kg body weight the first 2 months and about 5 mg/kg from month 3-6."( [Therapy of psoriatic osteoarthropathy with EHDP].
Altmeyer, P; Holzmann, H; Hör, G; Maul, FD; Thiers, G, 1985
)
0.27
" Combinations of calcitonin and disodium etidronate in conventional dosage seem to result in an additive suppressant effect on bone turnover and may be indicated for more active disease."( Paget's disease of bone. An update on management.
Hosking, DJ, 1985
)
0.54
"Paget's disease of bone in 51 patients was treated with ethane-1, hydroxy-1,1 diphosphonate (EHDP) for six months at a dosage of 5 mg/kg/day."( Treatment of Paget's disease of bone with ethane-1, hydroxy-1,1 diphosphonate (EHDP) at a low dosage (5 mg/kg/day).
Alexandre, CM; Chapuy, MC; Edouard, C; Johnston, CC; Meunier, PJ; Vignon, E, 1983
)
0.27
" Diphosphonate therapy at a dosage of 10 mg/kg/day when prescribed an average of 26 days after diagnosis did not prevent radiographically evident progression of heterotopic ossification."( Diphosphonate treatment for heterotopic ossification in spinal cord injury patients.
Alday, B; Garland, DE; Venos, KG; Vogt, JC, 1983
)
0.27
" These cases emphasise the importance of administering EHDP in low dosage for short periods only."( Diphosphonates and painful feet.
Evans, RA; MacDonald, D, 1983
)
0.27
" The medication is generally well tolerated and at the recommended dosage there is no evidence of increased fracture rate."( Use of etidronate (EHDP) in Paget's disease of bone.
Johnston, CC; Khairi, MR; Meunier, PJ, 1980
)
0.72
"Six patients with Paget disease of bone were treated with a 6-mo course of disodium-ethane-1-hydroxy-1, 1-diphosphate (EHDP) at a dosage of 5 mg/kg/day (one patient) or 20 mg/kg/day (five patients)."( An apparent 1,25-dihydroxyvitamin D-independent stimulation of intestinal calcium absorption in patients with Paget disease of bone during a short-term diphosphonate therapy.
Norman, DA; Pak, CY; Zerwekh, JE, 1981
)
0.26
" reduced the scanning hyperfixation of the active pagetic areas in 6 patients: it likewise more or less markedly reduced hyperosteoclastosis, with no apparent increase in the osteoid volume; two patients suffering from upper maxillary disease regressed clinically (dentures had become too large); headache and hypacusia were not modified; the response to the treatment seems to depend on three factors: the activity of the patient, the dosage used, and an individual factor which may be linked to the severity of the osteoidosis."( [Treatment of Paget's disease with 1-ethane-1-hydroxy-1-diphosphonate].
Basle, M; Bontoux, L; Bontoux-Carre, E; Jallet, P; Moreau, R; Renier, JC, 1982
)
0.26
" In one group of animals, EHDP treatment was discontinued after one year of dosage at 5 mg/kg/day given subcutaneously."( The long-term skeletal effects of EHDP in dogs.
Bevan, JA; Cloyd, GG; Flora, L; Hassing, GS; Parfitt, AM; Villanueva, AR, 1981
)
0.26
"005) of the femoral neck at all dosage levels."( Risedronate treatment does not increase microdamage in the canine femoral neck.
Burr, DB; Eastman, DF; Forwood, MR; Schwardt, JD; Smith, PN; Takano, Y, 1995
)
0.29
"To compare the efficacy and safety of tiludronate and etidronate at the same dosage (400 mg/day) for the treatment of active Paget's disease of bone."( Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone.
Devogelaer, JP; Dougados, M; Farrerons, J; Gennari, C; Kruse, HP; Mulder, H; Picot, C; Reginster, JY; Roux, C; Titeux, L, 1995
)
0.76
"Tiludronate at 400 mg/day for 3 months or 6 months is more effective than the same dosage of etidronate for 6 months in the treatment of Paget's disease."( Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone.
Devogelaer, JP; Dougados, M; Farrerons, J; Gennari, C; Kruse, HP; Mulder, H; Picot, C; Reginster, JY; Roux, C; Titeux, L, 1995
)
0.73
"Application of ion chromatography (IC) to the analysis of non-chromophoric bisphosphonate drugs in pharmaceutical dosage formulations is described."( Determination of bisphosphonate drugs in pharmaceutical dosage formulations by ion chromatography with indirect UV detection.
Bell, C; Brooks, MA; Chamberlin, SD; Forsyth, RJ; Ip, DP; Tsai, EW, 1994
)
0.29
" Mineralisation defects in forming bone may be avoided by the use of an initial dosage of 5 mg/kg/day for up to 6 months; dosages above 10 mg/kg/day should be limited to 3 months' duration, and dosages greater than 20 mg/kg/day should be avoided."( Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Dunn, CJ; Fitton, A; Sorkin, EM, 1994
)
0.29
" L-T4 treatment resulted in reduction in BMDs in the lumbar spine, tail, and femur as measured by dual energy X-ray absorptiometry, but there was no correlation with the dosage of L-T4 or the serum T4 level."( A rat model of thyroid hormone-induced bone loss: effect of antiresorptive agents on regional bone density and osteocalcin gene expression.
Kung, AW; Ng, F, 1994
)
0.29
"Using this relation, it is possible to predict thrombocytopenia by pretreatment bone scintigraphy and to adjust the dosage to each patient to avoid unacceptable toxicity."( Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations.
Blijham, GH; de Klerk, JM; Han, SH; Stokkel, MP; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1994
)
0.29
" Twenty-five patients took oral disodium etidronate in a daily dosage of 200 mg in two-month courses separated by two-month intervals, with 1 g/day elemental calcium."( [A one-year prospective study of disodium etidronate versus 17 beta estradiol in the prevention of postmenopausal osteoporosis].
Belange, G; Chaouat, D; Chaouat, Y; Danan, S; De Vernejoul, MC; Faures Quenet, B, 1993
)
0.82
" Determining the effective dosage is essential."( [Indications and limitations of non-hormonal treatments of osteoporosis].
Avouac, B,
)
0.13
" We have evaluated the effectiveness of three dosage regimes of aminohydroxypropylidene bisphosphonate (pamidronate) in 15 patients with extensive Paget's disease who had become refractory to conventional therapy."( Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.
Gunasekera, RD; Wimalawansa, SJ, 1993
)
0.29
" A pulsed dosage regimen was used during the 2-year period and the patients were followed up with otologic and audiometric examinations."( The effects of etidronate disodium on progressive hearing loss from otosclerosis.
Hoffer, ME; Holliday, M; Kennedy, DW, 1993
)
0.64
" Compared with gallium nitrate, pamidronate offers a more convenient dosing regimen, is less frequently associated with nephrotoxicity, and is less expensive."( Update on the medical treatment of hypercalcemia of malignancy.
Hall, TG; Schaiff, RA, 1993
)
0.29
"Although the function of normal bone marrow is affected by metastases in patients with metastatic bone disease, the MIRD model can be used to relate toxicity to the bone marrow absorbed dose after a therapeutic dosage of 186Re-HEDP."( Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
Blijham, GH; de Klerk, JM; Hoekstra, A; Rutgers, DH; van Dieren, EB; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1996
)
0.29
" A Phase 1 dosage escalation study was performed using 186Re-HEDP in patients with metastatic breast cancer."( Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
Blijham, GH; de Klerk, JM; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1996
)
0.29
" Rats were dosed concomitantly with indomethacin (40 mg/kg, subcutaneously) and an amino or pyridinyl bisphosphonate (orally at."( Nonclinical model for assessing gastric effects of bisphosphonates.
Berman, SK; Blank, MA; Ems, BL; Gibson, GW; Myers, WR; Phipps, RJ; Smith, PN, 1997
)
0.3
" This paper reports the results of dosage escalation studies with 186Re-HEDP as a bone-seeking radiopharmaceutical in patients with bone metastases originating from breast or prostate cancer with regard to toxicity, pharmacokinetics and bone marrow dosimetry and the palliating effect on bone pain."( Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
Blijham, GH; De Klerk, JM; Han, SH; Hoekstra, A; Quirijnen, JM; Van Dijk, A; Van Het Schip, AD; Van Rijk, PP; Zonnenberg, BA,
)
0.13
" Ethane 1-hydroxy-1, 1-bisphosphonate counteracted the effect of uranyl nitrate on oxygen-dependent and cobalt-dependent erythropoietin production, but did not correct the right shift of the dose-response relationship for exogenous erythropoietin induced by uranyl nitrate in the polycythemic rat."( Influence of bisphosphonate on the negative erythropoietic effects of uranyl nitrate.
Bozzini, CE; Frid, A; Giglio, MJ, 1997
)
0.3
" In these studies another formulation of the drug and other dosing instructions are used."( A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.
Christiansen, C; Clemmesen, B; Ravn, P; Reginster, JY; Taquet, AN; Zegels, B, 1997
)
0.3
" Serum and urine samples were obtained for 48 hours after dosing for risedronate analysis."( Risedronate gastrointestinal absorption is independent of site and rate of administration.
Bekker, PJ; Clay, ME; Dunlap, LE; Eusebio, RA; Mitchell, DY; Nesbitt, JD; Pallone, KA; Russell, DA, 1998
)
0.3
" Risedronate was well tolerated during the dosing phase of the study as evidenced by clinical observations, body weight gain and food consumption which were not significantly different from the vehicle controls."( Evaluation of the effects of risedronate on hepatic microsomal drug metabolizing enzyme activities following administration to rats for 14 days: lack of an induction response.
Hu, JK; Schwecke, WP; Smith, BJ, 1998
)
0.3
"Although further studies are necessary regarding the effects of etidronate on crystallization and crystal adhesion both in vivo and in vitro, and the appropriate schedule of dosing to prevent side effects, it is possible that etidronate may be useful in the treatment of urinary stones."( Effects of etidronate disodium on crystallizations in synthetic urine and calcium oxalate crystal adhesion to Madin-Darby canine kidney (MDCK) cells.
Ebisuno, S; Inagaki, T; Kohjimoto, Y; Komura, T; Nishihata, M; Nishikawa, T; Ohkawa, T, 1998
)
0.93
" The data show that there is a dose-response with risedronate: patients who received 30 mg oral risedronate for 28 days benefited most, with a mean percentage decrease in AP excess of 72."( Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study.
Bekker, PJ; Brown, JP; Hosking, DJ; Johnson, TD; Johnston, CC; Reginster, J; Ryan, WG; Ste-Marie, L, 1999
)
0.3
" No clear dose-response relationship was found."( 186Re-etidronate in breast cancer patients with metastatic bone pain.
Blijham, GH; de Klerk, JM; Han, SH; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonneberg, BA, 1999
)
0.78
" Of the six patients treated at the highest dosage schedules (three at 1510 MBq/m2 and three at 1665 MBq/m2), three showed a posttherapy decline in prostate-specific antigen of 50% or more."( Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer.
Curley, T; Daghighian, F; Goldsmith, SJ; Graham, MC; Larson, SM; Liu, GB; Scher, HI; Yeh, SD, 1999
)
0.3
"5-1 h before breakfast or 2 h after an evening meal support previous clinical studies where risedronate was found to have similar effectiveness using these dosing regimens."( The effect of dosing regimen on the pharmacokinetics of risedronate.
Clay, ME; Heise, MA; Melson, CW; Mitchell, DY; Nesbitt, JD; Pallone, KA; Russell, DA, 1999
)
0.3
" Oral dosing should not be substituted for intravenous administration in the treatment of malignant osteolysis."( Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000
)
0.31
" Serum samples were obtained for 72 h after dosing, and urine samples were collected for 72 h after dosing and then periodically for 6 weeks."( Effect of renal function on risedronate pharmacokinetics after a single oral dose.
Eusebio, RA; Kelly, SC; Mitchell, DY; Nesbitt, JD; Pallone, KA; Powell, JH; Russell, DA; St Peter, JV; Thompson, GA, 2000
)
0.31
"The objective of this study was to evaluate whether the pharmacological activity of cyclical etidronate therapy is sustained beyond the dosing period."( Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
Balena, R; Blake, GM; Fogelman, I; Herd, RJ, 2000
)
0.94
" These findings suggest that etidronate in clinical dosage may have an antiatherogenic action, at least in type 2 diabetes, although its mechanisms remain to be elucidated."( Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes.
Koshiyama, H; Minamikawa, J; Nakamura, Y; Tanaka, S, 2000
)
0.83
" The study was designed as a dose-response study, and the site-specific effects of immobilization and of treatment are described."( Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats.
Mackey, MS; Mosekilde, L; Phipps, RJ; Thomsen, JS, 2000
)
0.31
" The present study compared the potential for alendronate and risedronate to produce endoscopic upper GI mucosal irritation using the highest approved dosage regimens for the two agents."( An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae.
Graham, DY; Lanza, F; Malaty, HM; Musliner, T; Quan, H; Reyes, R; Sahba, B; Schwartz, H, 2000
)
0.31
" The oesophageal transit is rapid and given the rapid disintegration and gastric emptying, oesophageal contact occurring via reflux of risedronate was unlikely since most, if not all, of the dosage form exited from the stomach within 30 min."( Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects.
Blackshaw, PE; Dansereau, RJ; Frier, M; Hathaway, S; Juan, D; Li, Z; Long, P; Perkins, AC; Spiller, RC; Wilson, CG, 2001
)
0.31
" The time course of changes in PTH levels following cessation of dosing was unaffected by calcium supplementation."( Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis.
Collette, J; Eastell, R; Ethgen, D; Reginster, JY; Roumagnac, I; Russell, RG; Zegels, B, 2001
)
0.31
" However, by this new scintigraphic quantification method, bone uptake and soft-tissue retention can be calculated separately, thus providing more detailed kinetic data and potentially improving the dosimetry of these radiopharmaceuticals in, for example, assessment of radiation dosage to bone and bone marrow."( Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner, W; Henze, E; Kampen, AM; Kampen, WU, 2001
)
0.31
" As a result of this concern, dosage forms are now being designed to exhibit minimal esophageal adhesion."( The in-vitro porcine adhesion model is not predictive of the esophageal transit of risedronate tablets in humans.
Crail, D; Dansereau, R; Lane, M; McCargar, L; Myers, W, 2001
)
0.31
"As our population ages, and the consumption of pharmaceutical products rises, the incidence of solid oral dosage forms lodging in the esophagus is likely to increase and may be formulation dependent."( The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water.
Blackshaw, PE; Dansereau, RJ; Frier, M; Hathaway, S; Li, Z; Perkins, AC; Spiller, RC; Vincent, RM; Wenderoth, D; Wilson, CG, 2001
)
0.31
" 3) INC induced Cbfa1-nuclear localization within hours; and in an in vivo experiment using ovariectomized mice, its 3 weeks dosing exhibited the same effect in tibial extracts."( Incadronate and etidronate accelerate phosphate-primed mineralization of MC4 cells via ERK1/2-Cbfa1 signaling pathway in a Ras-independent manner: further involvement of mevalonate-pathway blockade for incadronate.
Fujita, T; Fukuyama, R; Izumo, N; Koida, M; Meguro, T; Nakamuta, H; Yasutomi, C, 2001
)
0.66
" Etidronate was given cyclically (14-day courses in a dosage of 400 mg/d separated by 76-day intervals with calcium and vitamin D supplementation) and alendronate was given daily in a dosage of 10 mg/d."( Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.
Béra-Louville, A; Cortet, B; Delcambre, B; Gauthier, A; Gauthier, P; Marchandise, X, 2001
)
1.49
" Alendronate, however, can be given as a once-weekly dose, whereas risedronate is not yet available in this dosage form."( Role of alendronate and risedronate in preventing and treating osteoporosis.
Leonard, M; Licata, AA; Peters, ML, 2001
)
0.31
" We found, in dose-response studies, that alendronate and risedronate inhibit bone resorption (in pit assays) at doses tenfold lower than those reducing osteoclast number."( Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.
Halasy-Nagy, JM; Reszka, AA; Rodan, GA, 2001
)
0.31
" Also, the risk of these adverse GI tract events can be decreased by following the dosing instructions (e."( Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity.
Baker, DE, 2002
)
0.31
" A 70-mg once-weekly dosage form of alendronate has recently been approved and clinical experience with its gastrointestinal tolerability is ongoing."( What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.
Graham, DY, 2002
)
0.31
" This dosage was well tolerated with a low incidence of GI side effects."( Bone density changes with once weekly risedronate in postmenopausal women.
Delaney, MF; Hurwitz, S; LeBoff, MS; Shaw, J, 2003
)
0.32
"The purpose of this study was to determine compliance with dosing instructions, and the prevalence of possible adverse events, when risedronate is used in clinical practice."( Tolerability and compliance with risedronate in clinical practice.
Hamilton, B; McCoy, K; Taggart, H, 2003
)
0.32
" To assess the anti-fracture efficacy of this new regimen, we have analyzed the fracture data collected in an active controlled study of risedronate dosing regimens (the Once-a-Week study) using matched historical control data from previous placebo-controlled trials."( Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate.
Brown, J; Kasibhatla, C; Li, Z; Lindsay, R; Watts, NB, 2003
)
0.32
" The potent bisphosphonate zoledronate can be given at intervals of as long as 1 year and produces changes in bone density and in markers of bone turnover comparable with those seen with conventional daily oral dosing with alendronate or risedronate."( Bisphosphonates: new indications and methods of administration.
Reid, IR, 2003
)
0.32
"To compare the effects of alendronate (ALN) 70 mg once weekly (OW) and risedronate (RIS) 5 mg daily between-meal dosing on biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal women with osteoporosis."( Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
Adami, S; Andia, JC; Benhamou, L; Felsenberg, D; Hosking, D; Petruschke, RA; Reginster, JY; Rybak-Feglin, A; Santora, AC; Välimäki, M; Yacik, C; Zaru, L, 2003
)
0.32
" Therefore, the pharmacokinetic profile of risedronate was considered to show linearity in a dosage range of up to 20 mg."( Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies.
Cyong, JC; Gonsho, A; Ogura, Y; Orimo, H, 2004
)
0.32
"The efficacy and tolerability of risedronate once-a-week dosing (35 and 50mg) were compared with risedronate daily dosing (5mg) in a 2-year study in women with osteoporosis."( Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.
Brown, JP; Chines, AA; Hanley, DA; Harris, ST; Li, Z; Watts, NB, 2004
)
0.32
" Risedronate 35 mg once a week is considered the optimal dose want a once-a-week dosing regimen."( Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.
Brown, JP; Chines, AA; Hanley, DA; Harris, ST; Li, Z; Watts, NB, 2004
)
0.32
" We conclude that prophylactic treatment with risedronate in a training population at high risk for stress fracture using a maintenance dosage for the treatment of osteoporosis does not lower stress fracture risk."( The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits.
Burr, D; Finestone, A; Goldich, Y; Kaufman, S; Kreiss, Y; Liebergall, M; Milgrom, C; Novack, V; Pereg, D; Zimlichman, E, 2004
)
0.32
" The dosage of opiates was decreased in 77% of the patients and could be discontinued in 4 of them."( Palliative treatment of painful disseminated bone metastases with 186Rhenium-HEDP in patients with lung cancer.
Anagnostopoulou, US; Datseris, EI; Leondi, AH; Leontopoulou, SA; Papadaki, EK; Rapti, AS; Souvatzoglou, MA; Zerva, CJ, 2004
)
0.32
"The objective of this review is to present the clinical profiles of the once-weekly and once-daily dosing formulations of alendronate and risedronate, the 2 bisphosphonates currently available in the United States for the prevention and treatment of postmenopausal osteoporosis."( Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.
Emkey, R, 2004
)
0.32
"To evaluate pharmacists' knowledge of approved dosing information for cyclic etidronate, alendronate and risedronate in the treatment of postmenopausal osteoporosis; and to assess its relationship to demographic and pharmaceutical care factors."( Pharmaceutical care and community pharmacists' understanding of bisphosphonate dosing information.
Kendler, DL; Li, WW, 2004
)
0.55
"Fax-back questionnaire to evaluate pharmacists' knowledge of approved bisphosphonate dosing information and their involvement in pharmaceutical/patient care activities through independent indices."( Pharmaceutical care and community pharmacists' understanding of bisphosphonate dosing information.
Kendler, DL; Li, WW, 2004
)
0.32
"Mean bisphosphonate dosing knowledge score was 76 +/- 11% (mean +/- SD)."( Pharmaceutical care and community pharmacists' understanding of bisphosphonate dosing information.
Kendler, DL; Li, WW, 2004
)
0.32
"There is a wide range of knowledge of bisphosphonate dosing and delivery of pharmaceutical care amongst community pharmacists surveyed."( Pharmaceutical care and community pharmacists' understanding of bisphosphonate dosing information.
Kendler, DL; Li, WW, 2004
)
0.32
" Further work will be necessary to determine the optimal dosage and the optimal frequency for the treatment series."( [Effect of oral biphosphonates in patients with cystic fibrosis and low bone mineral density].
Audran, M; Duveau, E; Giniès, JL; Leblanc, M; Leboucher, B; Ringuier, B; Troussier, F, 2004
)
0.32
"Forty-four women who had undergone cementless total hip arthroplasty (THA) were selected for determination of the optimum dosage of etidronate in the treatment of stress shielding after surgery."( Efficacy of different dosing schedules of etidronate for stress shielding after cementless total hip arthroplasty.
Fuji, T; Masuhara, K; Yamaguchi, K; Yamasaki, S, 2005
)
0.8
" Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis."( Oral antiresorptive therapy.
Hosking, DJ; Pande, I, 2005
)
0.33
" Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis."( Oral antiresorptive therapy.
Hosking, DJ; Pande, I, 2004
)
0.32
" Our data show that ED at a dosage that suppresses bone metabolism markedly inhibits vascular calcification in rats with renal failure."( Effect of etidronate on aortic calcification and bone metabolism in calcitriol-treated rats with subtotal nephrectomy.
Aizawa, S; Hashiba, H; Kogo, H; Suzuki, Y; Tamura, H; Tamura, K, 2005
)
0.73
" Reducing oral bisphosphonate dosing frequency is one measure available to increase therapy convenience and practicality, with the hope of improving compliance and persistence."( Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Altman, R; Amonkar, MM; Cramer, JA; Hebborn, A, 2005
)
0.33
" However, compliance and persistence rates for both regimens were suboptimal, suggesting that less frequent dosing intervals may provide an opportunity to further improve the consistent use of bisphosphonate therapy."( Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Altman, R; Amonkar, MM; Cramer, JA; Hebborn, A, 2005
)
0.33
"Patients should be clearly warned that the prescribed dosing for fluticasone nasal spray should be carefully followed because overuse may cause serious side effects."( Systemic effects of fluticasone nasal spray: report of 2 cases.
Licata, AA,
)
0.13
" Although bisphosphonates are effective in treatment of osteoporosis, a strict instruction to patients on the dosage often results in their inadequate compliance with the therapy."( [Practical approaches to the osteoporosis treatment--instructions for drug use that draws the effect of the medicine].
Ijiri, S, 2005
)
0.33
" Nevertheless, the need to follow inconvenient dosing instructions every week could still hinder long-term compliance and therapeutic outcome."( Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM, 2006
)
0.33
"In this NH population, weekly risedronate administered using a between-meal dosing schedule reduced serum BSAP at 6 weeks of treatment; this effect was not observed at 12 weeks."( Between-meal risedronate does not alter bone turnover in nursing home residents.
Agrawal, S; Binkley, NC; Drinka, PJ; Engelke, JA; Krause, PF; Krueger, DC; Nest, LJ, 2006
)
0.33
"Chronic oral-dosed osteoporosis therapies are associated with poor adherence and persistence, regardless of age or dosing regimen."( Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
Boccuzzi, SJ; Downey, TW; Foltz, SH; Kahler, KH; Omar, MA, 2006
)
0.33
" The dosage regimen could be simplified by providing the two compounds in an integrated pack."( Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence.
Möller, G; Ringe, JD; van der Geest, SA, 2006
)
0.33
"In this multicenter, randomized, double-blind controlled trial, the efficacy and safety of once-weekly dosing with 17."( Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen.
Fukunaga, M; Itabashi, A; Kishimoto, H; Kushida, K; Nakamura, T; Nawata, H; Ohashi, Y; Ohta, H; Shiraki, M; Takaoka, K, 2006
)
0.33
"To compare medication persistence among patients receiving daily orally administered bisphosphonates with persistence among patients receiving weekly orally administered bisphosphonates to ascertain whether less frequent dosing is associated with better long-term treatment persistence."( Medication persistence with weekly versus daily doses of orally administered bisphosphonates.
Ettinger, MP; Gallagher, R; MacCosbe, PE,
)
0.13
"The inconvenience and complexity of required dosing procedures with oral bisphosphonate therapy for the prevention and treatment of osteoporosis are thought to be major factors that hinder medication persistence, and poor persistence is associated with suboptimal health-care outcomes."( Medication persistence with weekly versus daily doses of orally administered bisphosphonates.
Ettinger, MP; Gallagher, R; MacCosbe, PE,
)
0.13
"This study demonstrates that weekly dosing of orally administered bisphosphonates is associated with higher medication persistence than is daily dosing."( Medication persistence with weekly versus daily doses of orally administered bisphosphonates.
Ettinger, MP; Gallagher, R; MacCosbe, PE,
)
0.13
"The purposes of the present study were to differentiate the effects of pre-surgery treatment with risedronate and post-surgery treatment with a reduced dosing frequency of risedronate on trabecular bone loss in ovariectomized rats and to determine whether post-surgery treatment with a reduced dosing frequency of risedronate would have a beneficial effect on trabecular bone loss after pre-surgery treatment with risedronate by means of bone histomorphometric analysis."( Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats.
Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK, 2006
)
0.33
" The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate."( Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2007
)
0.34
" The variety of bisphosphonates currently available to us provides a wide range of tolerability and dosing profiles thus necessitating a thorough comparison of the most recent oral and intravenous bisphosphonates to differentiate the clinical context in which they should be used."( Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B, 2006
)
0.33
"The purpose of the present study was to examine the effect of pretreatment with risedronate and/or vitamin K2 and treatment continuation with reduced dosing frequency of the drugs on the early cancellous bone loss induced by ovariectomy (OVX) in rats."( Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study.
Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK, 2006
)
0.33
"Patients preferred a weekly dosing regimen with proven vertebral and non-vertebral fracture efficacy."( Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
Gold, DT; Safi, W; Trinh, H, 2006
)
0.33
" Inconvenient dosing was reported as a primary reason for discontinuation due to stopping or changing treatment in 19 (6."( Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women.
Chen, SH; Chen, YJ; Hall, BJ; Khan, MA; Kung, AW; Mirasol, R; Pasion, EG; Shah, GA; Sivananthan, SK; Tam, F; Tay, BK; Thiebaud, D, 2007
)
0.34
"A stability indicating, reversed-phase ion-pair high-performance liquid chromatographic method was developed and validated for the determination of risedronate in pharmaceutical dosage forms."( Development and validation of a reversed-phase ion-pair high-performance liquid chromatographic method for the determination of risedronate in pharmaceutical preparations.
Kyriakides, D; Panderi, I, 2007
)
0.34
" The dosing period was 4 weeks."( Additive effect of vitamin K2 and risedronate on long bone mass in hypophysectomized young rats.
Iwamoto, J; Sato, Y; Takeda, T; Yeh, JK, 2007
)
0.34
"To examine in a major cohort of patients whether or not musculoskeletal adverse effects (MAEs), similar to those seen in intravenous bisphosphonates (BP), might occur also in high dosage oral treatment regimens with alendronate (ALN) and risedronate (RSN)."( Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.
Bock, O; Boerst, H; Degner, C; Felsenberg, D; Stephan-Oelkers, M; Thomasius, FE; Valentine, SM,
)
0.13
" They are observed exclusively in patients starting ALN or RSN treatment with once weekly dosage regimens."( Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.
Bock, O; Boerst, H; Degner, C; Felsenberg, D; Stephan-Oelkers, M; Thomasius, FE; Valentine, SM,
)
0.13
"Risedronate 150 mg once a month is similar in efficacy and safety to daily dosing and may provide an alternative for patients who prefer once-a-month oral dosing."( Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, PD; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2008
)
0.35
" In two groups, anterior cruciate ligament transection was performed and half were left untreated, and the other half dosed with risedronate (0."( Preservation of periarticular cancellous morphology and mechanical stiffness in post-traumatic experimental osteoarthritis by antiresorptive therapy.
Boyd, SK; Doschak, MR; MacNeil, JA; Zernicke, RF, 2008
)
0.35
" Risedronate 75 mg twice monthly was effective and safe suggesting a new, convenient dosing schedule."( Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results.
Benhamou, CL; Delmas, PD; Eusebio, R; Man, Z; Matzkin, E; McClung, MR; Olszynski, WP; Recker, RR; Tlustochowicz, W; Zanchetta, J, 2008
)
0.35
"Patients perceive less frequent dosing as being more convenient."( Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results.
Benhamou, CL; Delmas, PD; Eusebio, R; Man, Z; Matzkin, E; McClung, MR; Olszynski, WP; Recker, RR; Tlustochowicz, W; Zanchetta, J, 2008
)
0.35
" Intravenous pamidronate is efficacious and has long been available, but its use is hindered by an impractical recommended dosing regimen of 30 mg IV over 4 h for three consecutive days."( A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson, A, 2008
)
0.35
" Bisphosphonates restore normal bone turnover and relieve bone pain, but oral formulations may be limited by complicated dosing regimens and poor gastrointestinal absorption."( A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson, A, 2008
)
0.35
" The effect of patient age, prescriber, initial dosing regimen, gastrointestinal adverse events, co-medication and fractures on non-compliance was investigated."( Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
Erkens, JA; Herings, RM; Olson, M; Penning-van Beest, FJ, 2008
)
0.35
" Daily dosing at start, increased number of co-medications and new use of intestinal agents in the year after starting bisphosphonates were independently associated with an increased odds of non-compliance."( Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
Erkens, JA; Herings, RM; Olson, M; Penning-van Beest, FJ, 2008
)
0.35
"This study revealed several determinants of non-compliance with bisphosphonates, the best controllable being the type of initial bisphosphonate, with daily dosing leading to more non-compliance than weekly dosing."( Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
Erkens, JA; Herings, RM; Olson, M; Penning-van Beest, FJ, 2008
)
0.35
" Although the products are labeled to be taken in the erect position, the semisupine position was included to simulate dosing in bedridden patients."( Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.
Atherton, CT; Blackshaw, PE; Dansereau, RJ; Hay, PD; Lawes, SC; Perkins, AC; Schnell, DJ; Spiller, RC; Wagner, LK, 2008
)
0.35
" Strategies to improve adherence to osteoporosis therapy include reducing dosing frequency, changing the route of administration, educating the patient about optimum bisphosphonate administration, and sending patient reminders."( Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
Martens, MG; Shaw, H, 2008
)
0.35
" Current dosing schedules are often inconvenient or impractical for patients."( Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.
Díaz-Curiel, M; Moro-Alvarez, MJ, 2008
)
0.35
"5 mg risedronate, and was well tolerated with favorable safety profiles compared with once-daily dosage regimen."( [Efficacy and tolerability of risedronate for the treatment of osteoporosis].
Kishimoto, H, 2008
)
0.35
"The present study was designed to evaluate the effects of risedronate, one of the most potent bisphosphonates, on alveolar bone resorption and angiogenesis in rats with experimental periodontitis to identify dose-response curves and treatment durations that can be therapeutic for periodontal therapy versus those associated with osteonecrosis of the jaws."( Effects of risedronate on alveolar bone loss and angiogenesis: a stereologic study in rats.
Ayas, B; Cetinkaya, BO; Gurgor, P; Keles, GC, 2008
)
0.35
" Six BPs are currently approved by the US Food and Drug Administration (FDA) for the treatment of Paget disease, and each has unique characteristics, such as response rates and requirements for dosage and administration, relevant to clinical outcome."( Paget disease of bone: therapeutic options.
Silverman, SL, 2008
)
0.35
" We next showed that risedronate given at a low dosage in animals bearing human B02-GFP breast tumors reduced osteolysis by inhibiting bone resorption, whereas therapy with higher doses also inhibited skeletal tumor burden."( Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
Clézardin, P; Daubiné, F; Ebetino, FH; Fournier, PG; Lundy, MW; Rogers, MJ, 2008
)
0.35
" Patients remarkably preferred therapy with a proven antifracture efficacy over a dosage frequency."( [Differences among bisfosfonates--specificity of risedronate (Actonel)].
Giljević, Z, 2008
)
0.35
" We also sought evidence of a dose-response relationship, where high adherence to or long-term use of aln led to more atypical femur fractures."( Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.
Abrahamsen, B; Eastell, R; Eiken, P, 2009
)
0.35
"Despite widely accepted efficacy of bisphophonates for osteoporotic fracture, patients treatment compliance has been low, especially, with daily regimen, in part because of the inconvenience associated with special dosing requirements of oral bisphophonates."( [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Okazaki, R, 2009
)
0.35
" Also reviewed are results of "bridging" studies designed to demonstrate the comparable efficacy of less frequent dosing regimens to increase bone mineral density and to reduce bone turnover."( Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Bilezikian, JP, 2009
)
0.35
"Two studies in postmenopausal women with osteoporosis provide information about the efficacy and safety of dosing oral risedronate 5 mg daily at a time other than before breakfast (i."( Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis.
Delmas, PD; Kendler, DL; Ringe, JD; Ste-Marie, LG; Taylor, EB; Vrijens, B, 2009
)
0.35
"Two studies in postmenopausal women with osteoporosis provide additional information about the efficacy and safety of dosing oral risedronate 5 mg daily at a time other than before breakfast (i."( Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis.
Delmas, PD; Kendler, DL; Ringe, JD; Ste-Marie, LG; Taylor, EB; Vrijens, B, 2009
)
0.35
"One study, flexible dosing, was a 6-month North American study in 730 patients randomized to before-breakfast dosing or flexible dosing later in the day."( Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis.
Delmas, PD; Kendler, DL; Ringe, JD; Ste-Marie, LG; Taylor, EB; Vrijens, B, 2009
)
0.35
"Results of these two studies demonstrate that overall flexible dosing of risedronate leads to smaller BMD gains compared to before-breakfast dosing."( Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis.
Delmas, PD; Kendler, DL; Ringe, JD; Ste-Marie, LG; Taylor, EB; Vrijens, B, 2009
)
0.35
" Once-monthly dosing options might increase treatment compliance and persistence."( Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
Beary, JF; Brown, JP; Burgio, DE; Darbie, LM; Matzkin, E; Racewicz, AJ; Ste-Marie, LG, 2009
)
0.35
"The aim of this study was to compare the tolerability and efficacy of 3 once-monthly risedronate dosing regimens with those of risedronate 5 mg/d."( Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
Beary, JF; Brown, JP; Burgio, DE; Darbie, LM; Matzkin, E; Racewicz, AJ; Ste-Marie, LG, 2009
)
0.35
" The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed."( Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Rackoff, P, 2009
)
0.35
" Interpretations from this study are limited by assumptions of persistence based on initial drug dosing and selected refill gap length measured."( Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.
Gold, DT; Safi, W; Trinh, H, 2009
)
0.35
" Fracture trials were initially performed with daily formulations, then bridging trials, in which the efficacy of intermittent dosing was assessed versus daily using validated surrogate endpoints for fracture."( Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Epstein, S; Jeglitsch, M; McCloskey, E, 2009
)
0.35
" Furthermore, ibandronate has demonstrated antifracture efficacy with intermittent dosing in two pooled analyses."( Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Epstein, S; Jeglitsch, M; McCloskey, E, 2009
)
0.35
"4), while the risk factor for OFH was a recent maximum GC dosage (>1."( Notable difference between the development of vertebral fracture and osteonecrosis of the femoral head in patients treated with high-dose glucocorticoids for systemic rheumatic diseases.
Amano, K; Kameda, H; Nagasawa, H; Ogawa, H; Sekiguchi, N; Suzuki, K; Takei, H; Takeuchi, T, 2009
)
0.35
" Based on these results, the effects of risedronate 35 mg once a week are similar in efficacy to daily dosing and may lead less adverse events than once-a-month dose."( Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
Abdelmoula, J; Bahlous, A; Bouzid, K; Sahli, H; Sallami, S, 2009
)
0.35
"5 mg once daily was well tolerated by patients with PDB, even though the dosage was seven times higher than that approved for the treatment of osteoporosis in Japan (2."( Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone.
Hashimoto, J; Takata, S; Yoh, K; Yoshimura, N, 2010
)
0.36
" Based on these results, the effects of risedronate 35 mg once a week are similar in efficacy to daily dosing and may lead less adverse events than once-a-month dose."( Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
Abdelmoula, J; Bahlous, A; Bouzid, K; Sahli, H; Sallami, S, 2009
)
0.35
" The method was validated and shown to be precise, accurate, and specific for the assay of risedronate in both bulk material and dosage forms."( Analysis of risedronate and related substances by ion-pair reversed-phase high-performance liquid chromatography with evaporative light-scattering detection.
Zhang, L, 2010
)
0.36
" Anastrozole was given at a dosage of 1 mg/day while oral risedronate was given at 35 mg/week."( Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010
)
0.36
" No dose-response relationship was present."( Stroke in relation to use of raloxifene and other drugs against osteoporosis.
Mosekilde, L; Pinholt, EM; Rejnmark, L; Schwartz, K; Vestergaard, P, 2011
)
0.37
" The increase seen for alendronate did not seem to be causal as no classical dose-response relationship was present."( Stroke in relation to use of raloxifene and other drugs against osteoporosis.
Mosekilde, L; Pinholt, EM; Rejnmark, L; Schwartz, K; Vestergaard, P, 2011
)
0.37
" Although less frequent dosing is preferred, other factors such as perceived efficacy, side effects, medication cost, availability of patient support programmes and route of delivery are equally important."( Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
Glendenning, P; Inderjeeth, CA; Lee, S, 2011
)
0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
"A dose escalation schedule was designed consisting of four dose levels with a standard dosage of docetaxel (75 mg/m(2) 3-weekly)."( A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).
Bloemendal, HJ; de Haas, MJ; de Klerk, JM; O'Sullivan, JM; van Bezooijen, BP; van Dodewaard-de Jong, JM; Wilson, RH, 2011
)
0.37
" However, an inverse dose-response relationship was seen, with an increased risk in those with low adherence (≤0."( Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?
Vestergaard, P, 2012
)
0.38
" Intravenous ibandronate suppressed serum CTX levels to a significantly greater degree at 7 days after the second dosing (0."( Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.
Bae, SJ; Kim, BJ; Kim, GS; Kim, HK; Koh, JM; Lee, SH; Lim, KH, 2012
)
0.38
" This adds to the range of risedronate dosing options and provides an alternative for patients who prefer once-a-month dosing."( Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, P; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2013
)
0.39
"After 2 years, treatment with risedronate 150-mg once a month provided similar efficacy and tolerability to daily dosing and provides an alternative for patients who prefer once-a-month oral dosing."( Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, P; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2013
)
0.39
" Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance."( Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
Balske, A; Burgio, DE; McClung, MR; Recker, RR; Wenderoth, D, 2013
)
0.39
"A meta-analysis of spine BMD dose-response relationships for alendronate, risedronate, and ibandronate was performed."( A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women.
Yates, J, 2013
)
0.39
"Animal data suggesting differences in potency and differences in approved oral dosage strengths for alendronate, risedronate, and ibandronate in the treatment of osteoporosis raise questions about their dose-response relationships and relative potencies in humans."( A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women.
Yates, J, 2013
)
0.39
"A meta-analysis of dose-response relationships for spine BMD increases for these three bisphosphonates was performed using data from 21 placebo-controlled trials that collectively included over 13,000 patients on active treatment and over 8,000 on placebo."( A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women.
Yates, J, 2013
)
0.39
" The combined effect of initial solution pH, 120-HEDP-BH dosage, and initial Au(III) concentration was investigated using response surface methodology (RSM), and the result showed that biomass dosage exerted a stronger influence on Au(III) uptake than those of initial pH and initial Au(III) concentration."( Biosorption of heavy metal ions onto agricultural residues buckwheat hulls functionalized with 1-hydroxylethylidenediphosphonic acid.
Liu, X; Qu, R; Wang, Z; Xu, Q; Yin, P; Zhang, J, 2012
)
0.38
" This monthly regimen may provide a more convenient dosing schedule to some patients with postmenopausal osteoporosis."( A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data.
Balske, AM; Benhamou, CL; Delmas, PD; Eusebio, R; Man, Z; Matzkin, E; McClung, MR; Olszynski, WP; Recker, R; Tlustochowicz, W; Zanchetta, JR, 2013
)
0.39
"Risedronate, an anti-osteoporotic drug, is associated with low patient compliance due to the upper gastrointestinal side-effects and stringent dosing regimes."( Risedronate-loaded Eudragit S100 microparticles formulated into tablets.
Cruz, L; Ferreira, LM; Mattiazzi, J; Pohlmann, L; Rolim, CM; Silva, CB; Velasquez, AA, 2014
)
0.4
" To achieve a high scale inhibition rate, the HEDP dosage must be increased when the test temperature exceeds 100 °C."( Application of 1-hydroxyethylidene-1, 1-diphosphonic acid in boiler water for industrial boilers.
Li, MD; Zeng, B; Zhang, H; Zhao, JM; Zhu, ZP, 2013
)
0.39
"We observed three cohorts of women aged 65 years and older who initiated once-a-week dosing of bisphosphonate therapy; (1) patients adherent to alendronate (n = 21,615), (2) patients adherent to risedronate (n = 12,215), or (3) patients filling only a single bisphosphonate prescription (n = 5,390) as a referent population."( Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2013
)
0.39
" There was no relation between dosage and age (p=0."( Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study.
Blaisse, RJ; de Wit, R; Erjavec, Z; Gerritse, FL; Los, M; Meulenbeld, HJ; Roodhart, JM; Smilde, TJ; van der Velden, AM, 2013
)
0.39
"Fifty-three patients received university pharmacy blinded medication for three months: 5 mg risedronate or placebo one dosage and 1 g calcium carbonate and 800IE cholecalciferol per day."( Risedronate does not enhance fixation or BMD in revision cups: randomised study with three years follow-up.
Digas, G; Kärrholm, JN; Saari, TM,
)
0.13
"This report describes bone safety and histomorphometric data across different dose levels and dosing frequencies of risedronate."( Bone safety with risedronate: histomorphometric studies at different dose levels and exposure.
Chavassieux, P; Lundy, MW; McClung, MR; Recker, RR; Ste-Marie, LG, 2015
)
0.42
" The low oral bioavailability and known dosing limitations due to food interactions of bisphosphonates have led to development of an oral delayed-release dose form of risedronate 35 mg to be taken weekly, before or after breakfast."( Bone safety with risedronate: histomorphometric studies at different dose levels and exposure.
Chavassieux, P; Lundy, MW; McClung, MR; Recker, RR; Ste-Marie, LG, 2015
)
0.42
"The aim of this study was to examine the level of compliance and persistence in patients with postmenopausal osteoporosis (OP) receiving daily risedronate (5 mg) with either fixed dosing of three different timing regimens (A: before breakfast; B: in-between meals; C: before bedtime) or with flexible dosing and the effect on urinary N-terminal telopeptide of Type 1 collagen (NTX-1)."( Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: A multicenter, prospective, parallel group study.
Lorenc, R; Oral, A, 2015
)
0.42
"A flexible dosing with daily risedronate appears be a valuable option in terms of compliance and persistence for patients with postmenopausal OP."( Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: A multicenter, prospective, parallel group study.
Lorenc, R; Oral, A, 2015
)
0.42
" This study shows the importance of patient stratification to establish absorbed dose-response correlations and indicates the potential to individualise treatment of bone metastases with radiopharmaceuticals according to patient-specific imaging and dosimetry."( Phase I/II trials of
Chittenden, SJ; Dearnaley, DP; Denis-Bacelar, AM; Divoli, A; Du, Y; Flux, GD; Johnson, B; McCready, VR; O'Sullivan, JM, 2017
)
0.46
" Administration of risedronate gastric-resistant does not require fasting, and this more convenient dosing administration may explain its improved efficacy."( Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
Alam, A; Boolell, M; Gauthier, G; Palacios, S; Thomasius, F; Vekeman, F, 2022
)
0.72
"Up to half of patients do not follow complex dosing instructions of immediate-release bisphosphonates used for the prevention of osteoporotic fractures, which can result in suboptimal effectiveness."( Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
Alam, A; Boolell, M; Gauthier, G; Palacios, S; Thomasius, F; Vekeman, F, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (36 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care36

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Hempz Scalp Care Herbal Conditioner Tea Tree & Chamomile -- 17 fl ozHempzBeauty & Personal Careaminomethyl propanol, iodopropynyl butylcarbamate, citric acid, acetic acid, cetearyl alcohol, cetyl alcohol, chlorphenesin, citric acid, tocopherol, panthenol, disodium EDTA, etidronic acid, tocopherol, glycerin, PEG-4, dimethicone, hydroxyethylcellulose, menthol, octyldodecanol, phenoxyethanol, laureth-9, sodium acetate, stearyl alcohol2024-11-29 10:47:42
Hempz Triple Moisture Herbal Conditioner Fresh Citrus -- 17 fl ozHempzBeauty & Personal Careiodopropynyl butylcarbamate, citric acid, acetic acid, benzyl benzoate, cetearyl alcohol, cetyl alcohol, chlorphenesin, citric acid, tocopherol, panthenol, disodium EDTA, etidronic acid, tocopherol, glycerin, PEG-4, dimethicone, hydroxyethylcellulose, limonene, linalool, octyldodecanol, phenoxyethanol, sodium acetate, sodium benzoate, stearyl alcohol2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 10C Swedish Blonde -- 135 mLHerbatintBeauty & Personal Careisopropyl alcohol, citric acid, cetyl alcohol, citric acid, ethanolamine, etidronic acid, imidazolidinyl urea, oleic acid, propylene glycol, simethicone, sodium benzoate, sodium metabisulfite2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 10N Platinum Blonde -- 135 mLHerbatintBeauty & Personal Care2 aminophenol, p phenylenediamine, ethanolamine, etidronic acid, propylene glycol2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 2N Brown -- 135 mLHerbatintBeauty & Personal Carecitric acid, p-phenylenediamine, cetyl alcohol, citric acid, ethanolamine, etidronic acid, imidazolidinyl urea, oleic acid, propylene glycol, simethicone, sodium benzoate, sodium metabisulfite2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 3N Dark Chestnut -- 135 mLHerbatintBeauty & Personal Careisopropyl alcohol, P-phenylenediamine, cetyl alcohol, ethanolamine, etidronic acid, imidazolidinyl urea, propylene glycol, simethicone, sodium benzoate2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 4C Ash Chestnut -- 135 mLHerbatintBeauty & Personal Care2-methylresorcinol, p-aminophenol, p-phenylenediamine, ethanolamine, etidronic acid, propylene glycol2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 4D Golden Chestnut -- 135 mLHerbatintBeauty & Personal Careascorbic acid, ethanolamine, etidronic acid, propylene glycol, resorcinol, sodium sulfite2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 4M Mahogany Chestnut -- 135 mLHerbatintBeauty & Personal Care2-amino-3-hydroxypyridine, m-aminophenol, p-aminophenol, p-phenylenediamine, cetyl alcohol, ethanolamine, etidronic acid, imidazolidinyl urea, methyl benzoate, propylene glycol, simethicone2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 4N Chestnut -- 135 mLHerbatintBeauty & Personal Carep-phenylenediamine, cetyl alcohol, ethanolamine, etidronic acid, imidazolidinyl urea, oleic acid, propylene glycol, simethicone, sodium benzoate2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 4R Copper Chestnut -- 135 mLHerbatintBeauty & Personal Careascorbic acid, ethanolamine, etidronic acid, propylene glycol, resorcinol, sodium sulfite2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 5D Light Golden Chestnut -- 135 mLHerbatintBeauty & Personal Careethanolamine, etidronic acid, propylene glycol, resorcinol2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 6D Dark Golden Blonde -- 135 mLHerbatintBeauty & Personal Careascorbic acid, ethanolamine, etidronic acid, propylene glycol, resorcinol, sodium sulfite2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 6N Dark Blonde -- 135 mLHerbatintBeauty & Personal Carecitric acid, cetyl alcohol, citric acid, ethanolamine, etidronic acid, imidazolidinyl urea, oleic acid, propylene glycol, simethicone, sodium benzoate, sodium metabisulfite2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 7D Golden Blonde -- 135 mLHerbatintBeauty & Personal Careascorbic acid, ethanolamine, etidronic acid, propylene glycol, resorcinol, sodium sulfite2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 7N Blonde -- 135 mLHerbatintBeauty & Personal Careisopropyl alcohol, citric acid, p-phenylenediamine, cetyl alcohol, citric acid, ethanolamine, etidronic acid, imidazolidinyl urea, oleic acid, propylene glycol, simethicone, sodium metabisulfite2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 8D Light Golden Blonde -- 135 mLHerbatintBeauty & Personal Careascorbic acid, ethanolamine, etidronic acid, propylene glycol, resorcinol, sodium sulfite2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 8N Light Blonde -- 135 mLHerbatintBeauty & Personal Careisopropyl alcohol, citric acid, cetyl alcohol, citric acid, ethanolamine, etidronic acid, imidazolidinyl urea, oleic acid, propylene glycol, simethicone, sodium benzoate2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 9DR Copperish Gold -- 135 mLHerbatintBeauty & Personal Carecaprylyl glycol, citric acid, ascorbic acid, cetyl alcohol, citric acid, ethanolamine, etidronic acid, lanolin, propylene glycol2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 9N Honey Blonde -- 135 mLHerbatintBeauty & Personal Careisopropyl alcohol, citric acid, p-phenylenediamine, cetyl alcohol, citric acid, etidronic acid, oleic acid, propylene glycol, simethicone, sodium metabisulfite2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel FF3 Plum -- 135 mLHerbatintBeauty & Personal Care2-methylresorcinol, p-aminophenol, p-phenylenediamine, ethanolamine, etidronic acid, propylene glycol2024-11-29 10:47:42
Tints of Nature Permanent Hair Colour 10N Natural Platinum Blonde -- 4.4 fl ozTints of NatureBeauty & Personal Care2-methylresorcinol, orange, citric acid, p-phenylenediamine, chamomile, ascorbic acid, benzyl alcohol, citric acid, comfrey, tocopherol, panthenol, ethanolamine, ethylhexylglycerin, etidronic acid, tocopherol, glyceryl laurate, oleic acid, phenoxyethanol, sodium sulfite, urea2024-11-29 10:47:42
Tints of Nature Permanent Hair Colour 1N Natural Black -- 4.4 fl ozTints of NatureBeauty & Personal CareOrange, Citric Acid, p-Phenylenediamine, Chamomile, Ascorbic Acid, Benzoic Acid, Benzyl Alcohol, Cetyl Alcohol, Citric Acid, Cocamidopropyl Betaine, Comfrey, Tocopherol, Dehydroacetic Acid, Panthenol, Dioleyl Phosphate, Ethanolamine, Ethylhexylglycerin, Etidronic Acid, Tocopherol, Glycerin, Glyceryl Laurate, Oleic Acid, Phenoxyethanol, Propanediol, Sodium Benzoate, Sodium Sulfite, Stearyl Alcohol2024-11-29 10:47:42
Tints of Nature Permanent Hair Colour 2N Natural Darkest Brown -- 4.4 fl ozTints of NatureBeauty & Personal Careorange, m-aminophenol, 4-amino-2-hydroxytoluene, citric acid, p-phenylenediamine, chamomile, ascorbic acid, benzyl alcohol, citric acid, comfrey, tocopherol, panthenol, ethanolamine, ethylhexylglycerin, etidronic acid, tocopherol, glyceryl laurate, oleic acid, phenoxyethanol, sodium sulfite, urea2024-11-29 10:47:42
Tints of Nature Permanent Hair Colour 3N Natural Dark Brown -- 4.2 fl ozTints of NatureBeauty & Personal Care2- methylresorcinol, orange, M-aminophenol, citric acid, p-phenylenediamine, chamomile, ascorbic acid, benzyl alcohol, citric acid, comfrey, tocopherol, panthenol, ethylhexylglycerin, etidronic acid, tocopherol, glyceryl laurate, oleic acid, phenoxyethanol, sodium sulfite, urea2024-11-29 10:47:42
Tints of Nature Permanent Hair Colour 4C Medium Ash Brown -- 4.4 fl ozTints of NatureBeauty & Personal Care2- methylresorcinol, orange, M-aminophenol, citric acid, p-phenylenediamine, chamomile, ascorbic acid, benzyl alcohol, citric acid, comfrey, tocopherol, panthenol, ethylhexylglycerin, etidronic acid, tocopherol, glyceryl laurate, oleic acid, phenoxyethanol, sodium sulfite, urea2024-11-29 10:47:42
Tints of Nature Permanent Hair Colour 4CH Rich Chocolate Brown -- 4.4 fl ozTints of NatureBeauty & Personal Care2- methylresorcinol, orange, M-aminophenol, citric acid, p-phenylenediamine, chamomile, ascorbic acid, benzyl alcohol, citric acid, comfrey, tocopherol, panthenol, ethylhexylglycerin, etidronic acid, tocopherol, glyceryl laurate, oleic acid, phenoxyethanol, sodium sulfite, urea2024-11-29 10:47:42
Tints of Nature Permanent Hair Colour 4M Medium Mahogany Brown -- 4.4 fl ozTints of NatureBeauty & Personal Careorange, 4-amino-2-hydroxytoluene, p-aminophenol, citric acid, p-phenylenediamine, chamomile, ascorbic acid, benzyl alcohol, citric acid, comfrey, tocopherol, panthenol, ethanolamine, ethylhexylglycerin, etidronic acid, tocopherol, glyceryl laurate, oleic acid, phenoxyethanol, sodium sulfite, urea2024-11-29 10:47:42
Tints of Nature Permanent Hair Colour 4N Natural Medium Brown -- 4.2 fl ozTints of NatureBeauty & Personal Care2- methylresorcinol, orange, M-aminophenol, citric acid, p-phenylenediamine, chamomile, ascorbic acid, benzyl alcohol, citric acid, comfrey, tocopherol, panthenol, ethylhexylglycerin, etidronic acid, tocopherol, glyceryl laurate, oleic acid, phenoxyethanol, sodium sulfite, urea2024-11-29 10:47:42
Tints of Nature Permanent Hair Colour 5D Light Golden Brown -- 4.4 fl ozTints of NatureBeauty & Personal Care2-methylresorcinol, orange, m-aminophenol, 4-amino-2-hydroxytoluene, p-aminophenol, citric acid, p-phenylenediamine, chamomile, ascorbic acid, benzyl alcohol, citric acid, comfrey, tocopherol, panthenol, ethanolamine, ethylhexylglycerin, etidronic acid, tocopherol, glyceryl laurate, oleic acid, phenoxyethanol, sodium sulfite, urea2024-11-29 10:47:42
Tints of Nature Permanent Hair Colour 5N Natural Light Brown -- 4.4 fl ozTints of NatureBeauty & Personal Carem-Aminophenol, 4-amino-2 hydroxytoluene, citric acid, p-Phenylenediamine, chamomile, ascorbic acid, benzyl alcohol, citric acid, comfrey, tocopherol, panthenol, ethanolamine, ethylhexylglycerin, etidronic acid, tocopherol, glyceryl laurate, oleic acid, phenoxyethanol, sodium sulfite, urea2024-11-29 10:47:42
Tints of Nature Permanent Hair Colour 5R Rich Copper Brown -- 4.4 fl ozTints of NatureBeauty & Personal Care2-methylresorcinol, orange, m-aminophenol, 4-amino-2-hydroxytoluene, p-aminophenol, citric acid, p-phenylenediamine, chamomile, ascorbic acid, benzyl alcohol, citric acid, comfrey, tocopherol, panthenol, ethanolamine, ethylhexylglycerin, etidronic acid, tocopherol, glyceryl laurate, oleic acid, phenoxyethanol, sodium sulfite, urea2024-11-29 10:47:42
Tints of Nature Permanent Hair Colour 6C Dark Ash Blonde -- 4.2 fl ozTints of NatureBeauty & Personal Care2- methylresorcinol, orange, M-aminophenol, citric acid, p-phenylenediamine, chamomile, ascorbic acid, benzyl alcohol, citric acid, comfrey, tocopherol, panthenol, ethylhexylglycerin, etidronic acid, tocopherol, glyceryl laurate, oleic acid, phenoxyethanol, sodium sulfite, urea2024-11-29 10:47:42
Tints of Nature Permanent Hair Colour 6N Natural Dark Blonde -- 4.4 fl ozTints of NatureBeauty & Personal Care2- methylresorcinol, orange, M-aminophenol, citric acid, p-phenylenediamine, chamomile, ascorbic acid, benzyl alcohol, citric acid, comfrey, tocopherol, panthenol, ethylhexylglycerin, etidronic acid, tocopherol, glyceryl laurate, oleic acid, phenoxyethanol, sodium sulfite, urea2024-11-29 10:47:42
Tints of Nature Permanent Hair Colour 7N Natural Medium Blonde -- 4.4 fl ozTints of NatureBeauty & Personal Care2- methylresorcinol, orange, M-aminophenol, citric acid, p-phenylenediamine, chamomile, ascorbic acid, benzyl alcohol, citric acid, comfrey, tocopherol, panthenol, ethylhexylglycerin, etidronic acid, tocopherol, glyceryl laurate, oleic acid, phenoxyethanol, sodium sulfite, urea2024-11-29 10:47:42
Tints of Nature Permanent Hair Colour 8N Natural Light Blonde -- 4.4 fl ozTints of NatureBeauty & Personal Care2- methylresorcinol, orange, M-aminophenol, citric acid, p-phenylenediamine, chamomile, ascorbic acid, benzyl alcohol, citric acid, comfrey, tocopherol, panthenol, ethylhexylglycerin, etidronic acid, tocopherol, glyceryl laurate, oleic acid, phenoxyethanol, sodium sulfite, urea2024-11-29 10:47:42

Roles (3)

RoleDescription
bone density conservation agentAn agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis.
chelatorA ligand with two or more separate binding sites that can bind to a single metallic central atom, forming a chelate.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
1,1-bis(phosphonic acid)Any member of the class of phosphonic acids in which a carbon atom is directly attached to two phosphonic acid groups. They are analogues of pyrophosphates (with the central oxygen atom replaced by a carbon atom) and like pyrophosphates they tend to have a strong affinity for bone, so are frequently used for their antiresorptive and hypocalcaemic properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency63.09570.631035.7641100.0000AID504339
acid sphingomyelinaseHomo sapiens (human)Potency14.125414.125424.061339.8107AID504937
GLI family zinc finger 3Homo sapiens (human)Potency17.29900.000714.592883.7951AID1259369
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency3.54810.707912.194339.8107AID720542
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency30.76250.003041.611522,387.1992AID1159552
farnesoid X nuclear receptorHomo sapiens (human)Potency55.18980.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency61.37930.000229.305416,493.5996AID1259244
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency14.12540.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency15.41780.000723.06741,258.9301AID743085
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency19.95260.050127.073689.1251AID588590
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency40.53340.005612.367736.1254AID624032
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency35.48130.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency1.25890.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency61.37930.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency61.37930.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Type IV secretion-like conjugative transfer relaxase protein TraI Escherichia coli SMS-3-5Ki0.00300.00200.00270.0030AID328050
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (80)

Assay IDTitleYearJournalArticle
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1226176Half life in human plasma at 0.015 mg/kg, iv2015ACS medicinal chemistry letters, Apr-09, Volume: 6, Issue:4
Structural requirements for bisphosphonate binding on hydroxyapatite: NMR study of bisphosphonate partial esters.
AID328056Cytotoxicity against tetracycline-resistant F plasmid positive Escherichia coli JS102007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID328057Cytotoxicity against streptomycin-resistant F plasmid deficient Escherichia coli JS42007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1894079Anti-osteoclast activity rat assessed as inhibition of bone resorption relative to control2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID328053Inhibition of Escherichia coli F plasmid TraI relaxase Y16F mutant assessed as oriT ssDNA cleavage at 200 nM2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID328055Inhibition of conjugate DNA transfer between tetracycline-resistant F plasmid positive Escherichia coli JS10 to streptomycin-resistant F plasmid deficient Escherichia coli JS42007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID328059Selectivity ratio, ratio of EC50 for inhibition of conjugate DNA transfer between Escherichia coli JS10 and Escherichia coli JS4 to EC50 for Escherichia coli JS102007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID328050Inhibition of Escherichia coli F plasmid TraI relaxase Y16F mutant assessed as oriT ssDNA cleavage by competitive inhibition assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328054Inhibition of Escherichia coli F plasmid TraI relaxase Y16F mutant assessed as oriT ssDNA cleavage at 200 nM2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID328061Selectivity ratio, ratio of EC50 for Escherichia coli JS4 to ratio of EC50 for inhibition of conjugate DNA transfer between Escherichia coli JS10 and Escherichia coli JS42007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID55429Ability to inhibit growth of Dictostelium discoideum.2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1226174Binding affinity to hydroxyapatite at 3.2 to 3.7 mM after 1 hr by NMR analysis relative to control2015ACS medicinal chemistry letters, Apr-09, Volume: 6, Issue:4
Structural requirements for bisphosphonate binding on hydroxyapatite: NMR study of bisphosphonate partial esters.
AID184809Bone resorption activity in rats.2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID328060Selectivity ratio, ratio of EC50 for Escherichia coli JS10 to ratio of EC50 for inhibition of conjugate DNA transfer between Escherichia coli JS10 and Escherichia coli JS42007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328058Selectivity ratio, ratio of EC50 for Escherichia coli JS4 to EC50 for Escherichia coli JS102007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,659)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990657 (24.71)18.7374
1990's526 (19.78)18.2507
2000's964 (36.25)29.6817
2010's442 (16.62)24.3611
2020's70 (2.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.13 (24.57)
Research Supply Index8.11 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index75.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials510 (18.09%)5.53%
Reviews369 (13.09%)6.00%
Case Studies281 (9.97%)4.05%
Observational5 (0.18%)0.25%
Other1,654 (58.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]